[
    {
        "page_number": 1,
        "text": "1\nANTICOAGULATION\nMTAC(AC-MTAC)\nPROTOCOL\n2ndEDITION(2020)PHARMACEUTICALSERVICEPROGRAM\nMINISTRYOFHEALTHMALAYSIA"
    },
    {
        "page_number": 2,
        "text": "1January2020\n©AllRightsReserved\nThisisapublicationofthePharmaceuticalServicesProgram,\nMinistryofHealthMalaysia.\nEnquiriesaretobedirectedtotheaddressbelow.Permissionisherebygrantedto\nreproduceinformationcontainedhereinprovidedthatsuchreproductionbegivendue\nacknowledgementandshallnotmodifythetext.\nPharmaceuticalServicesProgram\nMinistryofHealthMalaysia\nLot36,JalanUniversiti,\n46200PetalingJaya,Selangor,Malaysia\nTel:603–78413200Fax:603–79682222\nWebsite:www.pharmacy.gov.my"
    },
    {
        "page_number": 3,
        "text": "2FOREWORD\nThisAnticoagulationMedicationTherapyAdherence\nClinic(AC-MTAC)Protocol2ndEditionisacommitment\nandcollectivehardworkoftheClinicalPharmacy\nWorkingCommittee(CardiologySubspecialty).Itisa\nrebrandingofWarfarinMTAC(WMTAC)wherethe1st\neditionofprotocolwaspublishedinyear2010.\nWarfarinMTAC(WMTAC)isoneofthemost\nestablishedMTACserviceinMalaysia.Untilnow,there\nare82hospitalsand12healthclinicsfromMinistryof\nHealthMalaysiacurrentlyofferingthisservice.Over\ntheyear,thetreatmentoptionsforanticoagulationtherapyhasevolvedand\nadvancedduetonewdiscoveriesofdirectoralanticoagulants(DOACs)suchas\nDabigatran,RivaroxabanandApixaban.Hence,thepharmacyserviceon\nmonitoringanticoagulationtherapyshouldalsobeimprovedandexpanded.\nThisprotocolservesasaguidancetoallexistingornewfacilitiesthatoffer\nAnticoagulantMTACservices.Ithasoutlinedtheentirestandardoperating\nproceduresanddocumentationsneededforimplementationofAC-MTACinMOH\nfacilities.ItalsoincludesseveralchecklistsforDOACscounselling,guidanceon\nmedicationdosageadjustmentstogetherwithmonitoringandevaluation\nprocedures.\nInshort,Iamgladthatthecommitteemembershavetakentheinitiativeto\nupgradeandimprovetheWarfarinMTACProtocoltoAnticoagulationMTAC(AC-\nMTAC)Protocol.IwouldliketocongratulatetheCardiologyPharmacyCommittee\nfortheircontributionandcommitmentofthispublication.Ihopethatthe\npharmacistscanutilisethisprotocolasareferenceduringtheimplementationof\nAC-MTAC.\nThankyou.\nDR.ROSHAYATIBINTIMOHAMADSANI\nDirector\nPharmacyPractice&DevelopmentDivision\nMinistryofHealthMalaysia"
    },
    {
        "page_number": 4,
        "text": "3ADVISOR\nDR.ROSHAYATIBINTIMOHDSANI\nDirectorofPharmacyPracticeandDevelopmentDivision\nPharmaceuticalServicesProgram,MOH\nEDITORS\nROZITABINTIMOHAMAD\nDeputyDirector\nPharmacyPracticeandDevelopmentDivision\nPharmaceuticalServicesProgramme,MOH\nNORHASNIBTHARON\nSeniorPrincipalAssistantDirector\nPharmacyPracticeandDevelopmentDivision\nPharmaceuticalServicesProgramme,MOH\nANGELINETANMENGWAH\nSeniorPrincipalAssistantDirector\nPharmacyPracticeandDevelopmentDivision\nPharmaceuticalServicesProgramme,MOH\nSHAKIRINBINTISHAIKRAHMAT\nSeniorPrincipalAssistantDirector\nPharmacyPracticeandDevelopmentDivision\nPharmaceuticalServicesProgramme,MOH\nEXTERNALREVIEWER\nDRGARYLEE\nConsultantCardiologist\nHospitalSerdang"
    },
    {
        "page_number": 5,
        "text": "4CONTRIBUTORS\nDrSahimibtMohamed HospitalTengkuAmpuanAfzan\nNikAzleanbtNikIsmail HospitalRajaPerempuanZainabII\nKarenLeeWeeFang HospitalTuankuFauziah\nLimWoanJieh HospitalSultanahBahiyah\nChoongShiauFenn HospitalPulauPinang\nDrDorisa/pGeorgeVisuvasam HospitalRajaPerempuanBainun\nDrWardatibintiMazlanKepli HospitalSerdang\nNurulZaidahbtBadarudin HospitalPutrajaya\nNirmalaa/pJagan HospitalKualaLumpur\nAzurabintiAzlan HospitalTuankuJa’afar\nKamSinYoo HospitalMelaka\nSitiRosnahbintiSuradi HospitalSultanahAminah\nNurulZatiSyaidabtAbdulMajid HospitalTengkuAmpuanAfzan\nMazurabtHanapi HospitalKemaman\nAaronChangCheeMing PusatJantungSarawak\nChiJiaHoong HospitalQueenElizabethII"
    },
    {
        "page_number": 6,
        "text": "5Contents\nINTRODUCTION...................................................................................................................................7\nOBJECTIVES..........................................................................................................................................7\nGeneralObjective........................................................................................................................7\nSpecificObjectives......................................................................................................................8\nSCOPEOFSERVICE..............................................................................................................................8\nMANPOWERREQUIREMENT..............................................................................................................8\nAPPOINTMENT....................................................................................................................................9\nDISPENSING.........................................................................................................................................9\nOUTCOMESMEASUREMENT...............................................................................................................9\nDOCUMENTATION...............................................................................................................................9\nSTANDARDOPERATINGPROCEDURES................................................................................................9\nSelectionofPatient...................................................................................................................10\nRegistration...............................................................................................................................10\nBloodTest..................................................................................................................................10\nClinicOperation.........................................................................................................................11\nPatientEducation......................................................................................................................11\nMonitoringandEvaluation.......................................................................................................12\nDosageAdjustments.................................................................................................................12\nA.Warfarin............................................................................................................................12\nB.DOACs................................................................................................................................12\nC.TripleTherapy...................................................................................................................13\nD.ConversionfromOneAnticoagulanttoAnother..............................................................13\nManagingBleedingInAnticoagulationPatients.......................................................................13\nResponsibilitiesofPharmacist..................................................................................................13\nDispensing.................................................................................................................................14\nMissedappointment.................................................................................................................14\nAppendices........................................................................................................................................17\nAppendix1-ACMTAC/F1...........................................................................................................18\nAppendix2-ACMTAC/F2...........................................................................................................20\nAppendix3-ACMTAC/F3..........................................................................................................21\nAppendix4-ACMTAC/F4..........................................................................................................23"
    },
    {
        "page_number": 7,
        "text": "6Appendix5-PrescriberChecklistForDOACs...........................................................................25\nAppendix6–PharmacistChecklistForDOACs.........................................................................27\nAppendix7-ChecklistForWarfarinEducation.........................................................................30\nAppendix8-ChecklistForDabigatranEducation......................................................................35\nAppendix9-ChecklistForRivaroxabanEducation...................................................................40\nAppendix10–ChecklistForApixabanEducation.....................................................................45\nAppendix11–WarfarinTherapyGuide...................................................................................50\nAppendix12–WeeklyDosingChart.........................................................................................53\nAppendix13–WarfarinInteractions........................................................................................61\nAppendix14–PrescribingInformationforDabigatran............................................................63\nAppendix15–PrescribingInformationforRivaroxaban..........................................................66\nAppendix16-PrescribingInformationforApixaban...............................................................70\nAppendix17-TripleTherapyGuide.........................................................................................74\nAppendix18-ConversionofAnticoagulantsGuide..................................................................77\nAppendix19-AnticoagulationReversalGuide........................................................................78\nAppendix20–RecommendedDispensingLabel......................................................................83\nREFERENCES......................................................................................................................................84\nListofFigure\nFigure1-ACMTACWorkFlow.............................................................................................15\nFigure2-WarfarinDoseAdjustmentWorkFlow................................................................16"
    },
    {
        "page_number": 8,
        "text": "7INTRODUCTION\nAnticoagulationMedicationTherapyAdherenceClinic(ACMTAC)isapartof\nMedicationTherapyAdherenceClinic(MTAC)servicesprovidedbythePharmacy\nPracticeandDevelopmentDivision,MinistryofHealthcollaboratewithdoctorsin\nthemanagementofpatientsonanticoagulationtherapy.Itwasformerlyknownas\nWarfarinMTAC(WMTAC).Duetothediscoveryofdirectoralanticoagulants\n(DOACs)suchasDabigatran,RivaroxabanandApixabaninrecentyears1\npromptedtheClinicalPharmacyWorkingCommittee(CardiologySubspecialty)to\nreviseandcomeupwithAC-MTACProtocol.\nProperanticoagulationtherapyisessentialtopatientsinordertominimiseriskof\nthromboticeventsorhaemorrhagicevents.2Anticoagulationtherapywithwarfarin\nhasevolvedfromdoctor-managedclinictothecollaborationwithpharmacistto\nimprovepatient’stimeintherapeuticrange(TTR).3Maximumbenefitsofwarfarin\ntherapyisevidentwhenTTRis≥70%.4\nTheavailabilityofDOACseithertargetingFactorIIa/thrombin(Dabigatran)or\nFactorXa(RivaroxabanandApixaban)reducetheneedforfrequentmonitoringas\ncomparedtowarfarin.5Ithasfewerdruginteractionsandpredictable\npharmacokinetics.6Nevertheless,propermonitoringofpatientsonDOACisstill\nrequiredtoensurepatients’adherencetowardsDOACsandtopreventriskof\nbleeding.7\nThisprotocolwasdevelopedtoserveasaguidetoprovidestandardisedpractice\ninallACMTACinMinistryofHealth’s(MOH).Thisprotocolneedstobediscussed\nwiththerelevantheadsofdepartmentsandsubsequentlyendorsedbyHospital\nDirectorbeforeimplementationinthefacility.\nThisprotocolisonlyapplicabletodrugsregisteredunderMalaysiaDrugFormulary\n(FUKKM).Thisshouldinnowaybeusedtoreplaceclinicaljudgment.Physician,\ncardiologist,orhaematologistcanalwaysbeconsultedforspecificpatientswith\nmorecomplexregimens.\nOBJECTIVES\nGeneralObjective\nToprovideacomprehensiveguideontheimplementationofanticoagulation\nMTAC(ACMTAC)."
    },
    {
        "page_number": 9,
        "text": "8SpecificObjectives\n1.Toprovideadequateknowledgeandunderstandingonthepathophysiology\nofthromboembolismindiseaseswhichrequireanticoagulationtherapy.\n2.Toprovideknowledgeonanticoagulationtherapythatcanbeusedto\npreventthromboembolism.\n3.Toprovidecontinuityandenhancepatientcarethrougheducation,\nmonitoring,andclosefollow-uptopatientswhorequireanticoagulation\ntherapy.\n4.Tomaximizethebenefitsofanticoagulationtherapyandminimizethe\nadverseeffectandcomplicationsresultingfromanticoagulationtherapy.\n5.Toprovideconsultativeandeducationalservicestootherhealthcare\nprovidersonanticoagulantdrugmanagementandrelatedissues.\n6.Toconductresearchregardinganticoagulationtherapyandrelatedareas.\nSCOPEOFSERVICE\n1.Theclinicshalloperatebasedonagreedhospitalclinicdayinthe\nrespectivedepartments.\n2.Approachofteamworkpracticeshallbeadoptedconsistingofdoctors,\npharmacists,andotherrelevanthealthcareproviders.\n3.FollowupofpatientsintheclinicshallbebasedonACMTACschedule.\n4.Activitiesintheclinicincludesmedicationhistorytakingfordrugs,OTC,\ntraditionalorherbalmedicine,andsupplements,counselling,dosage\nadjustmentofwarfarinbasedonInternationalNormalizedRatio(INR),renal\nand/orliverprofile,signsandsymptomsofbleedingandthromboembolic\nevent,therapyduringelectiveprocedureanddispensingofanticoagulation\nmedications.\nMANPOWERREQUIREMENT\n1.Thenumberofpharmacistsshallbebasedonthenumberofpatients\nscheduledperday.(Recommendedpharmacist:patientratiois1:10).\n2.Minimumtwo(2)trainedpharmacistsinACMTACteamwhereatleastone\n(1)pharmacistwillbeondutyduringeachACMTACsession.\n3.Pharmacistspendsataverageof10to15minutespercasewhilelonger\ntimemightbeneededfornewcases(around30minutes)."
    },
    {
        "page_number": 10,
        "text": "9APPOINTMENT\nAllappointmentsarescheduledbythepharmacistsorwiththehelpofother\nhealthcareprovidersintheclinic.\nDISPENSING\nAnticoagulationmedicationshallbedispensedduringACMTACtothe\npatients/caregiver.\nOUTCOMESMEASUREMENT\n1.Thisserviceshallbecontinuouslyassessedtoensurethatpatientsare\nreceivingoptimalcare.\n2.Thetimetotherapeuticrange(TTR)forwarfarintreatmentinACMTAChas\ntoachieveatargetedTTRof≥70%.\nDOCUMENTATION\nIndividualclinicalnotesincludingtheanticoagulationtherapydosingchanges,\nINRandlaboratory(renalorliverfunction)resultsshallbenotedinpatients’\nmedicalrecords.Therelevantdocumentsalsoshallbemaintainedinthe\npatients’medicalrecords:\n1.ACMTACReferralForm(ACMTAC/F1)–Appendix1\n2.ACMTACFirstVisitForm(ACMTAC/F2)–Appendix2\n3.ACMTACFollow-upVisitForm(ACMTAC/F3)–Appendix3\n4.MissedAppointmentSheet(ACMTAC/F4)–Appendix4\n5.PrescriberChecklistforDOACs–Appendix5\n6.PharmacistChecklistforDOACs–Appendix6\nSTANDARDOPERATINGPROCEDURES\nTheworkflowofACMTACisasshowninFigure1.Tenmainstagesinvolved\nare:\n1.Selectionofpatient\n2.Registration"
    },
    {
        "page_number": 11,
        "text": "103.Bloodtest\n4.Clinicoperation\n5.Patienteducation\n6.Monitoringandevaluation\n7.Dosageadjustments\n8.Responsibilitiesofpharmacist\n9.Dispensing\n10.Missedappointment\nSelectionofPatient\n1.Allout-patientonanticoagulationtherapyinrelevantdisciplines.\n2.Forpatientwhostartedonanticoagulationtherapyintheward,referrals\nshouldbemadepriortodischargetoallowadequatetimeforcase\nreviewandpatienteducation.Astandardisedreferralform(ACMTAC/F1)\n–Appendix1canbeused.\n3.Allnewcasesfromotherclinicsorinstitutionsandanyinitiationof\nanticoagulantsneedtobediscussedwithprescriber(dependsonthe\nhospital/healthcentre).\n4.ThepharmacistshallobtainthePrescriberChecklistforDOACs\n(Appendix5)andPharmacistChecklistofDOACs(Appendix6)forall\nnewpatientsstartedwithDOACsandcompletetheform.\nRegistration\n1.Patientsshallfollowthegeneralpoliciesandproceduresconcerning\nregistration.\n2.RegistryofpatientsattendingACMTACshallbekeptandupdatedatalltime.\nBloodTest\n1.Forwarfarinpatients,INRcanbedeterminedthroughpointofcare\ntesting(POCT)orcentrallaboratorytest.AllbloodsamplingsforINR\nreadingshouldbeperformedbyrelevanttrainedhealthcareproviders.\n2.Renaland/orliverprofileshouldbetakenpriortoscheduled\nappointmentwhenneeded."
    },
    {
        "page_number": 12,
        "text": "11ClinicOperation\n1.Adesignatedareawithminimalinterruptionstoensurepatient’sprivacy\nandconfidentiality.\n2.Storageareaforrelevantdocumentsandnecessaryitemsshallbe\nmadeavailable.\n3.Forallscheduledpatients,thecasenotesneedtobereviewedforbetter\nunderstandingofthetherapy.\nPatientEducation\n1.Educationofthepatientisanimportantprocessofensuringsafeand\neffectiveuseofanticoagulanttherapy.\n2.Educationshouldbeindividualisedandbasedonpatient’s\nunderstanding.\n3.EachpatientshallbeprovidedwithaBukuRawatanAntikoagulasi\n(availableinBahasaMalaysia,MandarinandTamil)orotherrelevant\nmaterialsuchasleaflet/pamphlets.\n4.Patienteducationshouldincludethefollowing:\nName,strength,anddescriptionofanticoagulanttablet.\nFrequencyofdoseandadministrationtime.\nHowtohandlemisseddoses.\nPurposeofanticoagulationtherapyandhowitworks.\nMedications/supplementsanddietaryinteractions.\nRecognitionofsymptomsofbleeding/thrombosis,adversereactions\nandtheappropriateprocedurestofollow.\nImportanceofcompliancewithanticoagulantsandclinic\nappointments.\nEmphasisontheimportanceoffollowupanddocumentation.\nEducatepatientsontheuseofanticoagulantsinpregnancyorbreast\nfeedingifnecessary.\n5.Checklistforpatientseducationaslistedbelow:-\nChecklistforWarfarinEducation-Appendix7\nChecklistforDabigatranEducation-Appendix8\nChecklistforRivaroxabanEducation-Appendix9\nChecklistforApixabanEducation-Appendix10"
    },
    {
        "page_number": 13,
        "text": "12MonitoringandEvaluation\n1.Patient’sresponsetoanticoagulationtherapyshallbeevaluatedthrough\nINRorrenalprofileandinformationgatheredfrompatient’sinterview\nusingACMTAC/F2(Appendix2)orACMTAC/F3(Appendix3)or\nPharmacistChecklistForDOACs(Appendix6).\n2.Thefollowingcriteriashallbeusedtoassesspatient’sresponseto\nanticoagulationtherapyanddetectanypotentialproblemspriorto\ndosageadjustments:\nSignsandsymptomsofhaemorrhageorthromboembolism\nChangeincondition(s)ordiseasestate\nRecentalterationsindiet,medications,tobaccooralcoholintake\nAlterationsinothermedicalproblemsorrecentillnesses\nCompliancewithwarfarinorDOACtherapy\nUpcomingsurgeryordentalprocedures.\nDosageAdjustments\nA.Warfarin\n1.ThewarfarindoseshallbeadjustedtomaintainINRwithinrange.(Refer\nWarfarinTherapyGuide-Appendix11).\n2.TheworkflowforwarfarindoseadjustmentasinFigure2.\n3.TheweeklydosingchartasintheAppendix12.\n4.Theexacttargetrangemustbeusedforallvalvereplacements,acute\norrecentVTE.Otherwise,extendedtargetrange(±0.2oftargetINR\nrange)canbeapplied.\n5.Doseadjustmentshallbeconsideredinthefollowinginstances:\nWhentwoconsecutiveINRvaluesaresub-therapeuticorsupra-\ntherapeuticdespitepriorcontrolbeinggood\nWhenpatientreferredforfollowupafterinitiationofanticoagulation.\nWhenthereiswarfarin-drugs/supplements/herbal/dietinteractions\n(ReferWarfarinInteraction-Appendix13).\nB.DOACs\n1.TheDOACsdoseshallbemaintainedasDosingGuide.\n2.Dosinginformationareaslistedbelow:-\nPrescribingInformationforDabigatran(Appendix14)"
    },
    {
        "page_number": 14,
        "text": "13PrescribingInformationforRivaroxaban(Appendix15)\nPrescribingInformationforApixaban(Appendix16)\n3.Doseadjustmentshallbeconsideredinthefollowinginstances:\nCreatinineclearance≤30ml/min\nOlderage\nHigherbleedingrisk\nC.TripleTherapy\n1.Theuseoftripleanti-thrombotictherapyafterACSandPCIinpatients\nonchronicoralanti-coagulationwillleadtohighriskofbleeding.\n2.Tripletherapybeyond6monthsafterPCIisnotrecommended.\n3.DosingguidecanrefertoTripleTherapyGuideline(Appendix17).\nD.ConversionfromOneAnticoagulanttoAnother\n1.TheconversionfromWarfarin,LMWHorUFHtoDOACsorviceversa\nshallbedoneaccordingtoConversionofAnticoagulantGuide\n(Appendix18).\nManagingBleedingInAnticoagulationPatients\n1.ReversalofanticoagulationwithWarfarinorDOACsshouldbedone\nbasedonbleedingeventsor/andINRvalue(ReferAppendix19).\nResponsibilitiesofPharmacist\n1.Thepharmacistwilleducatethepatientonanticoagulationtherapyat\ntheinitialvisitandreinforcethiseducationateachvisit.\n2.Thepharmacistwillmonitor:\nINRvalues(ReferAppendix11).\nriskofbleeding\nstoptheantiplatelet(ReferAppendix11)\nrenalorliverprofile(ReferAppendix14–16)\n3.Thepharmacistisauthorisedtotranscribewarfarinprescriptionsas\nneededwheretheprescriptionforwarfarinwillbecounter-signedbythe\nappointeddoctorformedico-legalrequirements(basedonlocalpolicy/\napproval).\n4.Thepatientshallbereferredtothedoctorinthefollowingsituations:"
    },
    {
        "page_number": 15,
        "text": "14Actualorsuspectedsignsandsymptomsofseverehaemorrhage\nregardlessofINRvalue.\nActualorsuspectedsignsandsymptomsofthromboembolism.\nINRvaluesover4.0oranyINRvalueatthediscretionofthe\nrespectivehospital.\nWhenpatientsneedtooverlapwithlowmolecularweightheparin\n(LMWH)duringwarfarininitiationorsub-therapeuticINR.\nWhenthedurationoftherapyhasbeencompleted.\nWhenpatientsconsistentlymissappointmentsorremainnon-\ncomplianttotherapy.\nPatientwhorequiresre-initiationforwarfarin.\nPatientwhorequiresconversionfromoneanticoagulanttoanother\nPatientswhoneedtoreduceDOACsdose.\nDispensing\n1.Pharmacistmustensurecorrectdose,quantityofwarfarinorDOAC\ntabletsbedispensed.\n2.Upondispensing,pharmacistshallemphasizedonthecorrectdose,\nfrequencyandtimeofadministration.\n3.Standardisedlabel(Appendix19)isrecommendedwhendispensing\nwarfarin.\n4.Patientshallbeprovidedwithasummaryofimportantinformationatthe\nendofeachACMTACsession.\n5.Patients’understandingandexpectationsshallbereassessedwhen\nnecessary.\nMissedappointment\n1.Contactpatientassoonaspossibleandrescheduleanewappointment\n(forfacilitiesthatofferACMTACorWMTAConceaweek).\n2.Allowpatienttowalk-induringthenextACMTACday(forfacilitiesthat\nofferACMTACorWMTACtwiceaweek).\n3.ReasonsofmissedappointmentshouldbedocumentedinMissed\nAppointmentSheet(Appendix4)"
    },
    {
        "page_number": 16,
        "text": "15Figure1-ACMTACWorkFlow"
    },
    {
        "page_number": 17,
        "text": "16Figure2-WarfarinDoseAdjustmentWorkFlow"
    },
    {
        "page_number": 18,
        "text": "17Appendices\nAppendix1ACMTACReferralForm(ACMTAC/F1)\nAppendix2ACMTAC1stVisitForm(ACMTAC/F2)\nAppendix3ACMTACFollow-UpVisitForm(ACMTAC/F3)\nAppendix4MissedAppointmentSheet(ACMTAC/F4)\nAppendix5PrescriberChecklistForDOACs\nAppendix6PharmacistChecklistForDOACs\nAppendix7ChecklistforWarfarinEducation\nAppendix8ChecklistforDabigatranEducation\nAppendix9ChecklistforRivoraxabanEducation\nAppendix10ChecklistforApixabanEducation\nAppendix11WarfarinTherapyGuide\nAppendix12WeeklyDosingChart\nAppendix13WarfarinInteraction\nAppendix14PrescribingInformationforDabigatran\nAppendix15PrescribingInformationforRivaroxaban\nAppendix16PrescribingInformationforApixaban\nAppendix17TripleTherapyGuide\nAppendix18ConversionofAnticoagulantGuide\nAppendix19GuidelineforTreatmentofBleedinginAnticoagulation\nPatients\nAppendix20RecommendedDispensinglabel"
    },
    {
        "page_number": 19,
        "text": "ANTICOAGULATIONMTAC(ACMTAC)PROTOCOL\n18Appendix1-ACMTAC/F1\nANTICOAGULATIONMEDICATIONTHERAPYADHERENCECLINIC\nREFERRALFORM\nPHARMACYDEPARTMENT,HOSPITAL……………\nDate\nPatientDetails\nName: Age: Race:M/I/C/O\nMRN: ICNo: Gender:M/FPhoneNo:\nOralAnticoagulantTherapy\nTypeofOralAnticoagulant Dateoforalanticoagulantstarted:\n□Warfarin:\nTargetINRRange\n□1.5–2.5 □2.0–3.0\n□2.5–3.5\n□Other(please\nspecify):…………□Dabigatran______mg\n□Apixaban______mg\n□Rivaroxaban______mgAnticipatedDuration:\nAnticipatedStopDate:\nOralAnticoagulantIndication\nWarfarintherapy\n¤ArterialEmbolism\n¤AtrialFibrillation\n¤DeepVeinThrombosis\n¤PulmonaryEmbolism\n¤HeartValveReplacement\n¤Coagulopathystate(describe):__________\n¤PulmonaryHypertension\n¤LeftVentricularClot\n¤VenousThrombosisofotherspecificVein\n¤Other(pleasespecify):_____________Dabigatran/Rivaroxaban/Apixabantherapy\n¤Non-valvularatrialfibrillation\n¤Preventionofvenousthromboembolismintotalknee/\nhipreplacementsurgery\n¤TreatmentofDeepVeinThrombosis(DVT)\n¤PreventionofRecurrentDVT/PulmonaryEmbolism\nClinicalInformation\nIsthispatientonTripleTherapy?Yes/No\n□DurationforTripleTherapy________Datetostop:__________DrugtoDiscontinue________\n□DurationforDoubleTherapy_______Datetostop:_________DrugtoDiscontinue________\nConcurrentIllness\n□CAD□Diabetes□Liverdisease□GIbleeds□HeartFailure□Hypertension\n□Hyper/Hypothyroidism□PepticUlcerDisease□RenalImpairment□SeizureDisorder\n□Other(pleasespecify):"
    },
    {
        "page_number": 20,
        "text": "ANTICOAGULATIONMTAC(ACMTAC)PROTOCOL\n19BleedingRiskFactors(Tickallthatapplies)1\n□Hypertensioni.e.UncontrolledBP(SystolicBP>160mmHg)-1point\n□Abnormalrenal/liverfunction–2point\n□Stroke-1point\n□Bleedingtendency-1point\n□LabileINR-1point\n□Elderly(Age>65)-1point\n□Drugs(eg.NSAID/Aspirin)orAlcohol-2point\nNotes:Maximumscore=9,Score≤2LowRisk,≥3HighRisk\nConcurrentDrugTherapy\nName/Dose/Frequency Interaction\nComments:\nPharmacist’sSignatureandStamp\nPhysicianReview&Notes\nReferringPhysician’sSignatureandStamp"
    },
    {
        "page_number": 21,
        "text": "ANTICOAGULATIONMTAC(ACMTAC)PROTOCOL\n20Appendix2-ACMTAC/F2\nANTICOAGULATIONMEDICATIONTHERAPYADHERENCECLINIC\n1STVISITFORM\nPHARMACYDEPARTMENT,HOSPITAL……………\nDateofVisit:\nPatientInformation\nName: Age: Race:M/C/I/\nOthers:____________\nMRN: ICNO: Gender:M/F\nAddress: TelephoneNo\nAnticoagulationPlan(PleaseChooseOne)\nWarfarin Dabigatran* Rivaroxaban* Apixaban*\nIndication:\nInitiationDate: AnticipatedStopDate: *Dose(DOAC):\nPlanDuration: INRTarget(forwarfarinonly):\nBaselineReadings\nSerumCreatinine(mol/L): TotalBilirubin(g/L):\nCreatinineClearance(mL/min): Albumin(g/L):\nALT(/L): AST(/L):\nCo-morbidconditions\nCo-morbidMedicalConditions:\nConcurrentMedications Interaction\nName/Dose/Frequency Yes/NoEffect\nYes/No\nYes/No\nYes/No\nYes/No\nYes/No\nObjectiveInformation\nCurrentdose(Warfarin):\nMonTueWedThurFriSatSunCorrectdosetaken:Y/N\nMonTueWedThurFriSatSun\nSubjectiveInformation"
    },
    {
        "page_number": 22,
        "text": "ANTICOAGULATIONMTAC(ACMTAC)PROTOCOL\n21Compliance□Good□Poor___________________Misseddosesinpast1week:□No□Yes\n______\nBleeding□No□Yes____________________Thrombosis□No□Yes\n_________________\nDrugInteraction□No□Yes____________________\nFood/Herbs/supplementInteraction□No□Yes_________________\nAlcoholconsumption?□No□Yes_______________ Smoker?□No□Yes\n____________________\nChangeinMedicalStatus/Illness□No□Yes_________________\nChangeinPhysicalActivity:□No□Yes_________________\nPregnancy/plantogetpregnant?□No□Yes____________________\nOthercomplain/PatientsPlans:Y/N(DescribeifYes)\nAssessment\nINRValue Sub-therapeuticWithinRange Supra-\ntherapeutic\nINR(Laboratory)/(PointofCare)\nPharmacistReview/Plan\nPlan□Maintaindose□Loadingdose_____________Withhold____day(s)\n□Increasedose_____________□Reducedose_________________\n□S/CEnoxaparin_______________\nTCA_____________Date______________\n□AdvicepatienttogotoEDifhadbleeding/thrombosissymptomsoranyproblems\nWarfarindoserecommended:\nMonTueWedThurFriSatSun\nPharmacist’sSignatureandStamp\nDoctorReview&Notes(Ifapplicable)\nPhysician’sSignatureandStamp"
    },
    {
        "page_number": 23,
        "text": "ANTICOAGULATIONMTAC(ACMTAC)PROTOCOL\n22Appendix3-ACMTAC/F3\nANTICOAGULATIONMEDICATIONTHERAPYADHERENCECLINIC\nFOLLOW-UPVISITFORM\nPHARMACYDEPARTMENT,HOSPITAL……………\nDateofVisit:\nPatientInformation\nName:\nMRN/IC:\nAge: Weight:\nIndication: INRTarget:\nDrug:\nWarfarin Dabigatran Rivaroxaban Apixaban\nMissedappointments:Y/N(Reasonformissedappointment)\nObjectiveInformation\nCurrentdose\na.DOAC___________________\nb.Warfarin:\nMonTueWedThurFriSatSunCorrectdosetaken:\n□Yes□No(DOAC)____________________\n□No(Warfarin):\nMonTueWedThurFriSatSun\nSubjectiveInformation\nCompliance□Good□Poor___________________Misseddosesinpast1week:□No□Yes\n______\nBleeding□No□Yes____________________Thrombosis□No□Yes\n_________________\nDrugInteraction□No□Yes____________________\nFood/Herbs/supplementInteraction□No□Yes_________________\nAlcoholconsumption?□No□Yes_______________ Smoker?□No□Yes\n____________________\nChangeinMedicalStatus/Illness□No□Yes_________________\nChangeinPhysicalActivity:□No□Yes_________________\nPregnancy/plantogetpregnant?□No□Yes____________________\nOthercomplain/PatientsPlans:Y/N(DescribeifYes)"
    },
    {
        "page_number": 24,
        "text": "ANTICOAGULATIONMTAC(ACMTAC)PROTOCOL\n23Assessment\nINRValue Sub-\ntherapeuticWithinRange Supra-therapeutic\nINR(Laboratory)/(PointofCare)\nPharmacistReview/Plan\nPlan□Maintaindose□Loadingdose_____________Withhold____day(s)\n□Increasedose_____________□Reducedose_________________\n□S/CEnoxaparin_______________\nTCA_____________Date______________\n□AdvicepatienttogotoEDifhadbleeding/thrombosissymptomsoranyproblems\nWarfarindoserecommended:\nMonTueWedThurFriSatSun\nPharmacist’sSignatureandStamp\nDoctorReview&Notes(Ifapplicable)\nPhysician’sSignatureandStamp"
    },
    {
        "page_number": 25,
        "text": "ANTICOAGULATIONMTAC(ACMTAC)PROTOCOL\n24Appendix4-ACMTAC/F4\nMISSEDAPPOINTMENTSHEET\nMISSEDAPPOINTMENT\nANTICOAGULATIONMTAC\nPharmacyDepartment,Hospital………………………………….\nDate Patient’sdetails Miss\nAppointment\n(Date)NewAppointment\n(date)Initials"
    },
    {
        "page_number": 26,
        "text": "ANTICOAGULATIONMTAC(ACMTAC)PROTOCOL\n25Appendix5-PrescriberChecklistForDOACs\nPRESCRIBERCHECKLISTFORDOACS\n(DABIGATRAN/RIVAROXABAN/APIXABAN)\nPATIENTSDEMOGHRAPIC\nPatient’sName: ICNo&RN:\nINRValue&Date: Age(Years):Weight(Kg):\nSerumCreatinine&Date(Baseline) ClCr(Ml/Min)\nLiverFunction&Date(Baseline)\nCHOICEOFANTICOAGULANT\nPleasetick(√)attherelevantbox\n☐Dabigatran,Dose_________mg\n☐Rivaroxaban,Dose__________mg\n☐Apixaban,Dose___________mg\nSTATUSOFANTICOAGULANTTHERAPY\n☐NewCase\n☐ChangefromWarfarintoDabigatran/Rivaroxaban/Apixaban\nPleasestatereason:\nINDICATION\n☐PreventionofStrokeandSystemicEmbolisminNon-ValvularAtrialFibrillation\n(IndicatedforDabigatran110mg&Dabigatran150mg,Rivaroxaban15mg&\nRivaroxaban20mg,Apixaban2.5mg&Apixaban5mg)\n☐PreventionofVTEeventsintotalkneereplacementortotalhipreplacementsurgery\npatient\n(IndicatedforDabigatran75mg&Dabigatran110mg,Rivaroxaban10mg)\n☐PreventionandTreatmentofRecurrentDVT/PEinAcuteDVT\n(IndicatedforDabigatran110mg&Dabigatran150mg,Rivaroxaban15mg&\nRivaroxaban20mg)"
    },
    {
        "page_number": 27,
        "text": "ANTICOAGULATIONMTAC(ACMTAC)PROTOCOL\n26CONTRAINDICATION\nDONOTstartanticoagulantagentifpatienthascondition(s)asstatedbelow:-\n☐Insufficiencyrenalfunction\n☐Abnormalhepaticfunction\n☐CrCl<30ml/min:Dabigatran/Rivaroxaban(DVT)\n☐Child-PughB&C:Rivaroxaban ☐Child-PughC:Apixaban\n☐CrCl<15ml/min:Rivaroxaban/Apixaban\n☐Activebleeding(<6months)(e.g:intracranialhemorrhage,RecentGIbleed)\n☐PregnancyorLactation\n☐Elevatedliverenzymes>3timesULN:Dabigatran\n☐Plannedforneuraxialanesthesiaorspinalpuncture\nSPECIALWARNINGS&PRECAUTIONS\n☐ActiveulcerativeGIdisease\n☐Congenitaloracquiredcoagulationdisorder\n☐Bacterialendocarditis\n☐Recentbiopsyormajortrauma(<6months)\n☐Brain,spinalorophthalmicsurgery\n☐Extremebodyweight:>110kg\n☐Lowbodyweight:<50kg\n☐Thrombocytopeniaorfunctionplateletdefect\nChecklistwhenSwitchingpatientfromwarfarintoDabigatranorRivaroxabanorApixaban:\n1.IndicationDabigatranRivaroxabanApixaban\na.TreatmentandRecurrentofDVT ☐INRmust\nbe<2☐INRmust\nbe≤2.5\nb.PreventionofStrokeandSystemicEmbolism\ninNon-ValvularAtrialFibrillation☐INRmust\nbe<2☐INRmust\nbe<3☐INRmust\nbe<2\n2.Patienthasbeeninformedtodiscontinuewarfarinimmediately☐\n3.Thebleedingriskandsymptomshasbeeninformedtothepatientincludingthenecessityfor\nfrequentrenalfunctionmonitoring☐\n(Specialist’ssignature) Date:"
    },
    {
        "page_number": 28,
        "text": "ANTICOAGULATIONMTAC(ACMTAC)PROTOCOL\n27Appendix6–PharmacistChecklistForDOACs\nPHARMACISTCHECKLISTFORDOACs\n(DABIGATRAN/RIVAROXABAN/APIXABAN)\n(Pleaseuseonechecklistperpatient)\nReferenceno.:\nPleasetick(√)attherelevantbox ☐Firstvisit☐Followup\nA.Patient’sBiodataandBaselineRenal/LiverFunction\nPatient’sName: ICNo&RN:\nINRValue&Date: Age(Years): Weight(Kg):\nSerumCreatinine&Date: CrCl(ml/min):\nLiverFunction&Date:\nB.ConcurrentMedications(inclusiveoftraditionalproductsandsupplements)\nDrugName/Dose/Frequency\nC.Patientcounseling\nA.DABIGATRAN8\nVisitNo\nDate\nTakethecapsuletwicedailyataboutthesametimeeveryday.\nRemindpatientsnottodiscontinueDabigatranwithoutinformingthehealth\nproviderwhoprescribeit.\nKeepDabigatranintheoriginalblisterpacktoprotectfrommoisture.Donotput\nDabigatraninpillboxes.(Dabigatrandeterioratesimmediatelywhenexposed\ntohumidity).\nInstructpatienttoremoveonlyonecapsulefromtheblisterpackatthetimeofuse.\nDonotcheworbreakthecapsulebeforeswallowing.Swallowcapsuleswholewith\nwater.Dabigatrancanbetakenwithorwithoutfood.\nIfadoseofDabigatranisnottakenatthescheduledtime,takeitassoonas\npossibleonthesameday.\nThemisseddosecanstillbetakenupto6hourspriortothenextdose.\nDonotdoubledosetomakeupforthemisseddose.\nDonotrunoutofDabigatran.Refilltheprescriptionbeforeitfinished.\nInformhealthcareproviderifthereisnewdrugsprescribed,proceduresplannedor\npregnancy.\nPleaseexplainthepossiblesideeffects(RefertoD,E&F)"
    },
    {
        "page_number": 29,
        "text": "ANTICOAGULATIONMTAC(ACMTAC)PROTOCOL\n28B.RIVAROXABAN9\nVisitno.:\nDate:\nAdvisepatientstotakeRivaroxabanexactlyasprescribed.Takethetablet\naboutthesametimeeveryday(advisablewiththeeveningmeal)\nRemindpatientsnottodiscontinueRivaroxabanwithoutinformingthehealth\nproviderwhoprescribeit.\nThe15mgand20mgRivaroxabantabletsshouldbetakenwithfood,whilethe\n10mgtabletcanbetakenwithorwithoutfood.\nIfadoseofRivaroxabanisnottakenatthescheduletime,administerthedose\nassoonaspossibleonthesamedayasfollows;\n1.Forpatientsreceiving15mgtwicedaily:Thepatientshouldtakethe\ndoseimmediatelytoensureintakeof30mgdaily,two15mgtabletsmay\nbetakenatonce.\n2.Forpatientsreceiving20mg,15mgor10mgoncedaily:\n3.Thepatientshouldtakethemisseddoseimmediatelyonthesameday\n(by12midnight).\nDonotrunoutofRivaroxaban.Refilltheprescriptionbeforeitfinished.\nInformhealthcareproviderifthereisnewdrugsprescribed,proceduresplanned\norpregnancy.\nPleaseexplainthepossiblesideeffects(RefertoD,E&F)\nC.APIXABAN10\nVisitno.:\nDate:\nAdvisepatientstotakeApixabanexactlyasprescribed.Takethetabletabout\nthesametimeeveryday\nRemindpatientsnottodiscontinueApixabanwithoutinformingthehealth\nproviderwhoprescribeit.\nIfadoseofApixabanisnottakenatthescheduledtime,takeitassoonas\npossibleonthesameday.\nDonotdoubledosetomakeupforthemisseddose.\nDonotrunoutofApixaban.Refilltheprescriptionbeforeitfinished.\nInformhealthcareproviderifthereisnewdrugsprescribed,proceduresplanned\norpregnancy.\nPleaseexplainthepossiblesideeffects(RefertoD,E&F)"
    },
    {
        "page_number": 30,
        "text": "ANTICOAGULATIONMTAC(ACMTAC)PROTOCOL\n29Forinitialvisit,pharmacisthastocounselbasedonthesepoints.For2ndvisitonwards,\npharmacisthastoassesspatient’sknowledge.\nVisitno.:\nDate:\nD.Symptomsofbleeding\nBruises\nGum,nosebleed\nHeadaches,dizzinessorweakness\nHaemoptysis\nHaematuria\nMelaena\nRedorblack,tarrystools\nE.Symptomsofrenalfailure\nExcessiveorrapidweightgain\nOedema\nDehydration\nNausea&vomiting\nPruritus\nF.Gastrointestinaladversereaction(ifapplicable)\nDyspepsia,burningornausea\nAbdominalpainordiscomfort\nEpigastricdiscomfort,GERD\nG.Comment\nVisitno./Date\nSign&stamp\nVisitno./Date\nSign&stamp\nVisitno./Date\nSign&stamp\nVisitno./Date\nSign&stamp"
    },
    {
        "page_number": 31,
        "text": "ANTICOAGULATIONMTAC(ACMTAC)PROTOCOL\n30Appendix7-ChecklistForWarfarinEducation\nCHECKLISTFORWARFARINEDUCATION11\nUseslaymantermsthroughout;medicaltermsareinparenthesis.\nItalicizednotesshouldonlybeaddressedifaskedbythepatient.\nIntroduction\nName____________\nPharmacistfrom____________\n“I’mheretoeducateyouanewdrugyouwillbestartingsooncalled\nwarfarin”\n“Haveyoubeentoldwhatthisdrugisfor?”\nWarfarinis…\nAbloodthinneralsoknownasananticoagulant.\nDecreasesformationofbloodclots\nBloodclotscancauseastroke,heartattack,orbloodclotsinthelegs\n(DVT)orlungs(PE).\nYouareaskedtotakewarfarinbecause…\nYoujustexperienced____________\nAlegclot(DVT)\nAlungclot(PE)\nAnarrhythmia(Atrialfirillation)\nAheartattack(MI)\nTheplacementofamechanicalorbioprostheticheartvalve.\nBytakingwarfarin,itwilltreatyour_________(currentevent)and\npreventyoufromhavinganotherclottingevent(thromboembolic\nevent).\nYourinitialwarfarindose…\nWillbedeterminedbyyourdoctororpharmacist.\nYourdosemaychangebasedonyourregularbloodtests."
    },
    {
        "page_number": 32,
        "text": "ANTICOAGULATIONMTAC(ACMTAC)PROTOCOL\n31Nomatterwhatthedose,youmusttakeyourwarfarineverydayand\natthesametimeeveryday(evening).\nIfyoumissadose,takethedoseassoonasyourememberorbefore\n12midnight.DONOTdoubleyourdosethenextdaytomake-upfor\nthemisseddose.\nWARFARINCANBETAKENWITHORWITHOUTFOOD\nYourregularbloodtests…\nWillcheckyourresponsetowarfarin(isyourbloodtoothinornotthin\nenough?;howquicklywillyoubloodclotonthedoseyouron?)\nThisbloodtestiscalledanINRtest(InternationalNormalizedRatio).\nThegoalistokeepyourINRbetweenacertainrangethatwillbe\ndeterminedbyyourdoctor.Thiswillassureusthatwarfarinis\neffectivelyworking.\nVTE(DVT,PE),AF:INRrange2-3\nMVRorAVRwithriskfactors(AF,lowEF,previousembolism,\nhypercoagulablestate):INRrange2.5-3.5.\nIfyoufalloutofthisrange,yourwarfarindosemaychange.\nItisveryimportantthatyoumeetallofyourappointmentssothemost\neffectivedoseisgiventoyou.\nYoumayneedtohaveyourbloodtestedmorefrequentlyatfirst;\nhowever,oncewedetermineyourdose,yourscheduled\nappointmentswillbelessfrequent.\nPossiblesideeffectsofwarfarinare…\nBleedingproblems,allergies,liverproblems,lowBP,swelling,\npaleness,fever,andrash.\nIfanyofthesesideeffectsorotherunusualeventoccursafterthe\nstartofwarfarin,alertyourhealthcareprovider.\nThesesideeffectscanbepreventedaslongasregularbloodtests\naredoneanddietisconsistenttoassureanappropriatedoseisgiven.\nThemostconcerningsideeffectisthebleeding,whichtheresultof\nthebloodisbeingtoothin.\nAlertyourhealthcareproviderifyouanyofthesesignsand\nsymptoms:-"
    },
    {
        "page_number": 33,
        "text": "ANTICOAGULATIONMTAC(ACMTAC)PROTOCOL\n32Nosebleeds\nHeadache,dizziness,orweakness\nBruising(carefulwithmachinery,sharpobjectoraggressive\nsports)\nBleedinggums(carefulwhenbrushingteeth–usesoft\ntoothbrush)\nPinkorbrownurine\nRedorblackstools\nVomitingbloodormaterialthatlookslikecoffeegrinds\nPain,swelling,ordiscomfort\nAvoidactivitiesthatmaycausebleeding(acupuncture,massage,\ncupping/‘bekam’)\nRaresideeffectinclude…\nDeathofskin(RARE;skinnecrosisorgangrene;canoccursoonafter\nstartingCoumadin(3-8days)becausebloodclotsformandblock\nbloodflowtoareaofthebody(highadiposetissue).Patientsmaybe\nproteinCdeficiency)\nPurpletoessyndrome(MORERARE;painfulpurplelesionsonthe\ntoe;occurs3-8weeksafterstartingwarfarin.Patientsmayhave\nvascularatherosclerosis.Warfarininducesbleedingintothe\ncholesterolplagueandcholesterolcrystalemboliarereleasedand\ntraveltothesmallarteriesofthefeetandhands.)\nManydrug/Overthecountermedicine(OTC)/herbals/vitaminscan\ninteractwithwarfarin\nTrytoavoidNSAIDs(ibuprofen,naproxen)andaspirinforpainor\ninflammationasthesecanincreaseyourriskforbleedingwhileon\nwarfarin.\nAlwaysalertyourhealthcareproviderbeforestartingorstoppingany\ndrug/OTC/herbal/vitaminagents."
    },
    {
        "page_number": 34,
        "text": "ANTICOAGULATIONMTAC(ACMTAC)PROTOCOL\n33Manyfoodscaninteractwithwarfarin\nDoyoueatalotofvegetablesorsalads?\nLargeamountsofgreenleafyvegetables,whichcontainhigh\namountsofvitaminK,canlowertheeffectsofwarfarin(vitaminK\nworksagainstorantagonizeswarfarin).\nTrytomaintainaconsistentdiet,trytoeatthesameamounttoleafy\nvegetableseveryday.\nAvoidcranberryjuiceorproductsandalcohol.\nAlwaysalertanyhealthcareprovideryouinteractwiththatyouare\nonwarfarin(surgical,medical,dental).\nSigns/symptomsofastroke(forpts.withAF,CVA,post-MI,or\nvalvereplacements)\nFacialdroop\nArmdrift\nSlurredspeech\nWeaknessornumbnessinextremities(usuallyunilateral,butmaybe\nbilateral)\nAbnormalorlossofvisionorhearing(usuallyunilateral,butmaybe\nbilateral)\nDifficultywalking(unsteadygait)\nIfyouexperienceanyofthesesymptomsgotoemergency\ndepartmentimmediately\nSign/symptomsofaDVTandPE(forpatientswitheitheraDVTor\nPE)\nDVT\nLegswelling\nLegpain/tenderness\nLegdiscoloration\nLegwarmtothetouch"
    },
    {
        "page_number": 35,
        "text": "ANTICOAGULATIONMTAC(ACMTAC)PROTOCOL\n34PE\nSuddenunexplaineddifficultybreathing\nCough\nRapidbreathing\nRapidheartrateorpalpitations\nChestpainwhenyoubreathin(pleuriticchestpain)\nCallyourdoctorimmediatelyorgototheemergencyroomifyou\nhaveanysignsofaDVT/PE\nAlwaysalertyourhealthcareproviderifyoumakechangesinyour\ndiet,exercise,ordrug/OTC/herbals/vitaminuse.\nFinalverificationofindication,dosing/administration,sideeffects,\ndrug/foodinteractions,andappropriatesigns/symptomsofVTE."
    },
    {
        "page_number": 36,
        "text": "ANTICOAGULATIONMTAC(ACMTAC)PROTOCOL\n35Appendix8-ChecklistForDabigatranEducation\nCHECKLISTFORDABIGATRANEDUCATION8\nUseslaymantermsthroughout;medicaltermsareinparenthesis.\nItalicizednotesshouldonlybeaddressedifaskedbythepatient.\nIntroduction\nName____________\nPharmacistfrom……………………………\n“I’mheretoeducateyouanewdrugyouwillbestartingsoon\ncalleddabigatran”\n“Haveyoubeentoldwhatthisdrugisfor?”\nDabigatranis…\nAbloodthinneralsoknownasananticoagulant.“ANTI”means\nagainstand“COAGULANT”referstotheclottingofblood\nDecreasesformationofbloodclots\nBloodclotscancauseastroke,heartattack,orbloodclotsinthe\nlegs(DVT)orlungs(PE).\nYouareaskedtotakedabigatranbecause…\nYoujustexperienced____________\nAtrialfibrillation,DVTorPE\nPeoplewithaheartrhythmproblemcalledatrialfibrillationareat\nincreasedriskofaclotformingintheheart.Aclotintheheart\ncandislodgeandcauseastroke.Theroleofdabigatranin\npatientswithatrialfibrillationistopreventformationofaclotin\ntheheartandlowertheriskofstroke.\nDabigatranisalsousedtopreventclotsafterhiporkneesurgery."
    },
    {
        "page_number": 37,
        "text": "ANTICOAGULATIONMTAC(ACMTAC)PROTOCOL\n36Howshouldthisdrugbetaken?\nKeepDabigatranintheoriginalblisterpacktoprotectfrom\nmoisture.DonotputDabigatraninpillboxes.(Dabigatran\ndeterioratesimmediatelywhenexposedtohumidity\nRemoveonlyonecapsulefromtheblisterpackatthetimeofuse.\nDonotcheworbreakthecapsulebeforeswallowing.Swallow\ncapsuleswholewithwaterwithorwithoutfood.\nForatrialfibrillation:Takedabigatrantwicedailyaboutthe\nsametimeeveryday.\nForhiporkneesurgery:Takedabigatranoncedaily.\nNEVERstoptakingdabigatranunlesstoldtodosobyyour\ndoctor.\nYoumightbeathigherriskforstrokeorotherclotformationfora\nshorttimeafterstoppingthismedicine.\nAskyourdoctororpharmacist,toexplainanythingthatyoudo\nnotunderstand.\nWhatshouldyoudoifyouforgettotakeadose?\nIfyouforgettotakeadose,takeitassoonasyourememberon\nthesameday.\nIftakingdabigatrantwicedailyandyouhavelessthan6hours\nbeforethenextdoseisdue,skipthemisseddose.\nNEVERtakeadoubledosetomakeupforthemisseddose\nPossiblesideeffectsofdabigatranare…\nThemostconcerningsideeffectisthebleeding,whichtheresult\nofthebloodisbeingtoothin.\nAlertyourhealthcareproviderifyouhavesignsandsymptomsof\nbleeding.\nPain,swelling,ordiscomfort\nHeadache,dizziness,orweakness\nBruising(carefulwithmachinery,sharpobjector\naggressivesports)"
    },
    {
        "page_number": 38,
        "text": "ANTICOAGULATIONMTAC(ACMTAC)PROTOCOL\n37Avoidactivitiesthatmaycausebleeding(acupuncture,\nmassage,cupping/‘bekam’)\nNosebleeds\nBleedinggums(carefulwhenbrushingteeth–usesoft\ntoothbrush)\nPinkorbrownurine\nRedorblackstools\nVomitingbloodormaterialthatlookslikecoffeeground\nOrallergicreaction.\nItchingorhives\nSwellinginyourface,hands,mouth,orthroat\nDifficultybreathingorchesttightness\nSkinrash\nDrug/OTC/herbals/vitaminscaninteractwithdabigatran\nAlwaysalertyourhealthcareproviderbeforestartingorstopping\nanyRx/OTC/herbal/vitaminagents.\nMakesureyourdoctorknowsifyoutakeanyofthesemedicines:\nFluconazole,Itraconazole,Ketoconazole\nSt.John’sWort\nCarbamazepine\nClarithromycin/Erythromycin\nRifampicin\nMedicinesforHIV/AIDSincluding:indinavir,lopinavir,\nritonavir\nUnlessinstructedbyyourdoctor,donottakedabigatranwith:\nWarfarin/Rivaroxaban/Apixaban\nYoumaybeatincreasedriskofbleedingifyoutakedabigatran\nwith:\nClopidogrel/Prasugrel/Ticagrelor/Ticlopidine\nDipyridamole\nDrugsthatdissolveclotsincluding:alteplase,reteplase,\nstreptokinase,tenecteplase"
    },
    {
        "page_number": 39,
        "text": "ANTICOAGULATIONMTAC(ACMTAC)PROTOCOL\n38Prescriptionandnon-prescriptionpainandarthritis\nmedicines:\nAspirin(yourdoctormayapproveofoncedaily\naspirinwithdabigatran)\nNSAIDS:ibuprofen,naproxen,celecoxib,diclofenac,\nindomethacin,ketoprofen,piroxicam,sulindac\nWhatotherprecautionsshouldIfollowwhileusingthisdrug?\nSerious,life-threateningbleedingcanoccurwithdabigatranuse.\nThereisanantidotetoreversetheeffectsofdabigatranwhichis\nIdarucizumab\nMakesureyourdoctorknowsifyouarepregnantor\nbreastfeeding.Dabigatranmaycauseharmtotheunbornbaby\nandmaybeharmfultobreastfedbabies.\nMakesureyourdoctorknowsifyouhavekidneydisease,liver\ndisease,astomachulcer,oranyothermedicalproblems.\nYoumaybleedandbruisemoreeasilywhileyoutakedabigatran.\nAvoidactivitiessuchasroughsportsorothersituationsthatcould\ncausebruising,cuts,orseriousbleeding.Reportanyfallsor\nblowstotheheadtoyourdoctorrightaway.Brushandflossyour\nteethgently.\nDonotallowanyoneelsetotakeyourmedicine\nAlwaysalertyourhealthcareproviderthatyouareondabigatran\nSigns/symptomsofastroke(forpts.withAF,CVA,post-MI,or\nvalvereplacements)\nFacialdroop\nArmdrift\nSlurredspeech\nWeaknessornumbnessinextremities(usuallyunilateral,but\nmaybebilateral)\nAbnormalorlossofvision/hearing(usuallyunilateral,butmay\nbebilateral)\nDifficultywalking(unsteadygait)"
    },
    {
        "page_number": 40,
        "text": "ANTICOAGULATIONMTAC(ACMTAC)PROTOCOL\n39Ifyouexperienceanyofthesesymptomsgotoemergency\ndepartmentimmediately\nSign/symptomsofaDVTandPE(forpatientswitheitheraDVTor\nPE)\nDVT\nLegswelling\nLegpain/tenderness\nLegdiscoloration\nLegwarmtothetouch\nPE\nSuddenunexplaineddifficultybreathing\nCough\nRapidbreathing\nRapidheartrateorpalpitations\nChestpainwhenyoubreathin(pleuriticchestpain)\nGotoemergencydepartmentimmediatelyifyouhaveanysignsof\nDVT/PE.\nAlwaysalertyourhealthcareproviderifyoumakechangestoyour\ndrug/OTC/herbals/vitaminuse.\nFinalverificationofindication,dosing/administration,sideeffects,\ndrug/foodinteractions,andappropriatesigns/symptomsofVTE."
    },
    {
        "page_number": 41,
        "text": "ANTICOAGULATIONMTAC(ACMTAC)PROTOCOL\n40Appendix9-ChecklistForRivaroxabanEducation\nCHECKLISTFORRIVAROXABANEDUCATION9\nUseslaymantermsthroughout;medicaltermsareinparenthesis.\nItalicizednotesshouldonlybeaddressedifaskedbythepatient.\nIntroduction\nName____________\nPharmacistfrom……………………………\n“I’mheretoeducateyouanewdrugyouwillbestartingsoon\ncalledrivaroxaban”\n“Haveyoubeentoldwhatthisdrugisfor?”\nRivaroxabanis…\nAbloodthinneralsoknownasananticoagulant.“ANTI”means\nagainstand“COAGULANT”referstotheclottingofblood\nDecreasesformationofbloodclots\nBloodclotscancauseastroke,heartattack,orbloodclotsinthe\nlegs(DVT)orlungs(PE).\nYouareaskedtotakerivaroxabanbecause…\nYoujustexperienced____________\nAnarrhythmia(Atrialfirillation)\nAlegclot(DVT)\nAlungclot(PE)\nPeoplewithaheartrhythmproblemcalledatrialfibrillationareat\nincreasedriskofaclotformingintheheart.Aclotintheheartcan\ndislodgeandcauseastroke.Theroleofrivaroxabaninpatients\nwithatrialfibrillationistopreventformationofaclotintheheart\nandlowertheriskofstroke."
    },
    {
        "page_number": 42,
        "text": "ANTICOAGULATIONMTAC(ACMTAC)PROTOCOL\n41Rivaroxabanisalsousedtotreatpeoplewhohaveclotsinblood\nvessels,usuallyinthelegs,arms,orlungs.Whileitdoesnot\ndissolveaclotthatalreadyexists,rivaroxabancanstoptheclot\nfromgettingworseandpreventnewclotsfromforming(yourbody\nnaturallydissolvesclots).\nRivaroxabanisalsousedtopreventclotsafterhiporknee\nsurgery.\nHowshouldthisdrugbetaken?\nRivaroxabancomesinoraltablets.\nForatrialfibrillation:Takerivaroxabanbymouthoncedailywith\ntheeveningmeal.\nForclotsinbloodvessels:Takerivaroxabanbymouthtwice\ndailywithmealsfor3weeksthenoncedailywiththeeveningmeal\nasdirectedbyyourdoctor\nForhiporkneesurgery:Takerivaroxabanbymouthoncedaily\nwithorwithoutfood\nNEVERstoptakingrivaroxabanunlesstoldtodosobyyourdoctor.\nYoumightbeathigherriskforstrokeorotherclotformationfora\nshorttimeafterstoppingthismedicine.\nAskyourdoctor,pharmacist,ornursetoexplainanythingthatyou\ndonotunderstand.\nWhatshouldyoudoifyouforgettotakeadose?\nIfyouforgettotakeadose,takeitassoonasyourememberon\nthesameday.\nIftakingrivaroxabantwicedailyandyouhavelessthan6hoursto\ngobeforethenextdoseisdue,skipthemisseddose.\nNEVERtakeadoubledosetomakeupforthemisseddose\nPossiblesideeffectsofrivaroxabanare…\nThemostconcerningsideeffectisthebleeding,whichtheresultof\nthebloodisbeingtoothin.\nAlertyourhealthcareproviderifyouhavesignsandsymptomsof\nbleeding."
    },
    {
        "page_number": 43,
        "text": "ANTICOAGULATIONMTAC(ACMTAC)PROTOCOL\n42Pain,swelling,ordiscomfort\nHeadache,dizziness,orweakness\nBruising(carefulwithmachinery,sharpobjector\naggressivesports)\nAvoidactivitiesthatmaycausebleeding(acupuncture,\nmassage,cupping/‘bekam’)\nNosebleeds\nBleedinggums(carefulwhenbrushingteeth–usesoft\ntoothbrush)\nPinkorbrownurine\nRedorblackstools\nVomitingbloodormaterialthatlookslikecoffeegrounds\nOrallergicreaction.\nItchingorhives\nSwellinginyourface,hands,mouth,orthroat\nDifficultybreathingorchesttightness\nSkinrash\nDrug/OTC/herbals/vitaminscaninteractwithrivaroxaban\nAlwaysalertyourhealthcareproviderbeforestartingorstopping\nanydrug/OTC/herbal/vitaminagents.\nMakesureyourdoctorknowsifyoutakeanyofthesemedicines:\nFluconazole/Itraconazole/Ketoconazole\nSt.John’sWort\nCarbamazepine\nClarithromycin/Erythromycin\nRifampicin\nMedicinesforHIV/AIDSincluding:indinavir,lopinavir,\nritonavir\nUnlessinstructedbyyourdoctor,donottakerivaroxabanwith:\nWarfarin/Dabigatran"
    },
    {
        "page_number": 44,
        "text": "ANTICOAGULATIONMTAC(ACMTAC)PROTOCOL\n43Youmaybeatincreasedriskofbleedingifyoutakerivaroxaban\nwith:\nClopidogrel/Prasugrel/Ticagrelor/Ticlopidine\nDipyridamole\nDrugsthatdissolveclotsincluding:alteplase,reteplase,\nstreptokinase,tenecteplase\nPrescriptionandnon-prescriptionpainandarthritis\nmedicines:\nAspirin(yourdoctormayapproveofoncedaily\naspirinwithrivaroxaban)\nNSAIDS:ibuprofen,naproxen,celecoxib,diclofenac,\nindomethacin,ketoprofen,piroxicam,sulindac\nWhatotherprecautionsshouldIfollowwhileusingthisdrug?\nSerious,life-threateningbleedingcanoccurwithrivaroxabanuse.\nThereisnoantidotetoreversetheeffectsofrivaroxaban.\nMakesureyourdoctorknowsifyouarepregnantorbreastfeeding.\nRivaroxabanmaycauseharmtotheunbornbabyandmaybe\nharmfultobreastfedbabies.\nMakesureyourdoctorknowsifyouhavekidneydisease,liver\ndisease,astomachulcer,oranyothermedicalproblems.\nYoumaybleedandbruisemoreeasilywhileyoutakerivaroxaban.\nAvoidactivitiessuchasroughsportsorothersituationsthatcould\ncausebruising,cuts,orseriousbleeding.Reportanyfallsorblows\ntotheheadtoyourdoctorrightaway.Brushandflossyourteeth\ngently.\nDonotallowanyoneelsetotakeyourmedicine\nAlwaysalertyourhealthcareproviderthatyouareonrivaroxaban.\nSigns/symptomsofastroke(forpatientswithAF,CVA,post-MI,or\nvalvereplacements)\nFacialdroop\nArmdrift\nSlurredspeech"
    },
    {
        "page_number": 45,
        "text": "ANTICOAGULATIONMTAC(ACMTAC)PROTOCOL\n44Weaknessornumbnessinextremities(usuallyunilateral,butmay\nbebilateral)\nAbnormalorlossofvision(usuallyunilateral,butmaybebilateral)\nAbnormalorlossofhearing(usuallyunilateral,butmaybebilateral)\nDifficultywalking(unsteadygait)\nIfyouexperienceanyofthesesymptomsgotoemergency\ndepartmentimmediately\nSign/symptomsofaDVTandPE(forpatientswitheitheraDVTor\nPE)\nDVT\nLegswelling\nLegpain/tenderness\nLegdiscoloration\nLegwarmtothetouch\nPE\nSuddenunexplaineddifficultybreathing\nCough\nRapidbreathing\nRapidheartrateorpalpitations\nChestpainwhenyoubreathin(pleuriticchestpain)\nAnxiety\nGotoemergencydepartmentimmediatelyifyouhaveanysignsof\nDVT/PE.\nAlwaysalertyourhealthcareproviderifyoumakechangesinyour\ndiet,exercise,ordrug/OTC/herbals/vitaminuse.\nFinalverificationofindication,dosing/administration,sideeffects,\ndrug/foodinteractions,andappropriatesigns/symptomsofVTE."
    },
    {
        "page_number": 46,
        "text": "ANTICOAGULATIONMTAC(ACMTAC)PROTOCOL\n45Appendix10–ChecklistForApixabanEducation\nCHECKLISTFORAPIXABANEDUCATION10\nUseslaymantermsthroughout;medicaltermsareinparenthesis.\nItalicizednotesshouldonlybeaddressedifaskedbythepatient.\nIntroduction\nName____________\nPharmacistfrom……………………………\n“I’mheretoeducateyouanewdrugyouwillbestartingsoon\ncalledapixaban”\n“Haveyoubeentoldwhatthisdrugisfor?”\nApixabanis…\nAbloodthinneralsoknownasananticoagulant.“ANTI”means\nagainstand“COAGULANT”referstotheclottingofblood\nDecreasesformationofbloodclots\nBloodclotscancauseastroke,heartattack,orbloodclotsinthe\nlegs(DVT)orlungs(PE).\nYouareaskedtotakeapixabanbecause…\nYoujustexperienced____________\nAnarrhythmia(Atrialfirillation)\nPeoplewithaheartrhythmproblemcalledatrialfibrillationareat\nincreasedriskofaclotformingintheheart.Aclotintheheartcan\ndislodgeandcauseastroke.Theroleofapixabaninpatientswith\natrialfibrillationistopreventformationofaclotintheheartand\nlowertheriskofstroke.\nApixabanisalsousedtopreventclotsafterhiporkneesurgery."
    },
    {
        "page_number": 47,
        "text": "ANTICOAGULATIONMTAC(ACMTAC)PROTOCOL\n46Howshouldthisdrugbetaken?\nApixabancomesinoraltablets.\nForatrialfibrillation,hiporkneesurgery:Takeapixabanby\nmouthtwiceaboutthesametimeeveryday.\nNEVERstoptakingapixabanunlesstoldtodosobyyourdoctor.\nYoumightbeathigherriskforstrokeorotherclotformationfora\nshorttimeafterstoppingthismedicine.\nAskyourdoctor,pharmacist,ornursetoexplainanythingthatyou\ndonotunderstand.\nWhatshouldyoudoifyouforgettotakeadose?\nIfyouforgettotakeadose,takeitassoonasyourememberon\nthesameday.\nIftakingapixabantwicedailyandyouhavelessthan6hourstogo\nbeforethenextdoseisdue,skipthemisseddose.\nNEVERtakeadoubledosetomakeupforthemisseddose\nPossiblesideeffectsofapixabanare…\nThemostconcerningsideeffectisthebleeding,whichtheresultof\nthebloodisbeingtoothin.\nAlertyourhealthcareproviderifyouhavesignsandsymptomsof\nbleeding.\nPain,swelling,ordiscomfort\nHeadache,dizziness,orweakness\nBruising(carefulwithmachinery,sharpobjector\naggressivesports)\nAvoidactivitiesthatmaycausebleeding(acupuncture,\nmassage,cupping/‘bekam’)\nNosebleeds\nBleedinggums(carefulwhenbrushingteeth–usesoft\ntoothbrush)\nPinkorbrownurine\nRedorblackstools\nVomitingbloodormaterialthatlookslikecoffeegrounds"
    },
    {
        "page_number": 48,
        "text": "ANTICOAGULATIONMTAC(ACMTAC)PROTOCOL\n47Orallergicreaction.\nItchingorhives\nSwellinginyourface,hands,mouth,orthroat\nDifficultybreathingorchesttightness\nSkinrash\nDrug/OTC/herbals/vitaminscaninteractwithapixaban\nAlwaysalertyourhealthcareproviderbeforestartingorstopping\nanydrug/OTC/herbal/vitaminagents.\nMakesureyourdoctorknowsifyoutakeanyofthesemedicines:\nVoriconazole\nItraconazole\nKetoconazole\nPosaconazole\nPhenytoin\nCarbamazepine\nPhenobarbital\nRifampicin\nMedicinesforHIV/AIDSincluding:ritonavir\nUnlessinstructedbyyourdoctor,donottakeapixabanwith:\nWarfarin\nDabigatran\nRivaroxaban\nYoumaybeatincreasedriskofbleedingifyoutakeapixabanwith:\nClopidogrel\nPrasugrel\nTicagrelor\nTiclopidine\nDipyridamole\nDrugsthatdissolveclotsincluding:alteplase,reteplase,\nstreptokinase,tenecteplase\nPrescriptionandnon-prescriptionpainandarthritis\nmedicines:"
    },
    {
        "page_number": 49,
        "text": "ANTICOAGULATIONMTAC(ACMTAC)PROTOCOL\n48Aspirin(yourdoctormayapproveofoncedaily\naspirinwithapixaban)\nNSAIDS:ibuprofen,naproxen,celecoxib,diclofenac,\nindomethacin,ketoprofen,piroxicam,sulindac\nWhatotherprecautionsshouldIfollowwhileusingthisdrug?\nSerious,life-threateningbleedingcanoccurwithapixabanuse.\nThereisnoantidotetoreversetheeffectsofapixaban.\nMakesureyourdoctorknowsifyouarepregnantorbreastfeeding.\nApixabanmaycauseharmtotheunbornbabyandmaybeharmful\ntobreastfedbabies.\nMakesureyourdoctorknowsifyouhavekidneydisease,liver\ndisease,astomachulcer,oranyothermedicalproblems.\nTellyourdoctors,dentists,orpharmaciststhatyouareon\napixaban.\nYoumaybleedandbruisemoreeasilywhileyoutakeapixaban.\nAvoidactivitiessuchasroughsportsorothersituationsthatcould\ncausebruising,cuts,orseriousbleeding.\nReportanyfallsorblowstotheheadtoyourdoctorrightaway.\nBrushandflossyourteethgently.\nDonotallowanyoneelsetotakeyourmedicine\nAlwaysalertyourhealthcareproviderthatyouareonapixaban.\nSigns/symptomsofastroke(forpts.withAF,CVA,post-MI,orvalve\nreplacements)\nFacialdroop\nArmdrift\nSlurredspeech\nWeaknessornumbnessinextremities(usuallyunilateral,butmay\nbebilateral)\nAbnormalorlossofvision(usuallyunilateral,butmaybebilateral)\nAbnormalorlossofhearing(usuallyunilateral,butmaybebilateral)\nDifficultywalking(unsteadygait)"
    },
    {
        "page_number": 50,
        "text": "ANTICOAGULATIONMTAC(ACMTAC)PROTOCOL\n49Ifyouexperienceanyofthesesymptomsgotoemergency\ndepartmentimmediately\nSign/symptomsofaDVTandPE(forpatientswitheitheraDVTor\nPE)\nDVT\nLegswelling\nLegpain/tenderness\nLegdiscoloration\nLegwarmtothetouch\nCallyourdoctorimmediatelyorgototheemergencyroomif\nyouhaveanysignsofaDVT\nPE\nSuddenunexplaineddifficultybreathing\nCough\nRapidbreathing\nRapidheartrateorpalpitations\nChestpainwhenyoubreathin(pleuriticchestpain)\nAnxiety\nGotoemergencydepartmentimmediatelyifyouhaveany\nsignsofaPE.\nAlwaysalertyourhealthcareproviderifyoumakechangesinyour\ndiet,exercise,ordrug/OTC/herbals/vitaminuse.\nFinalverificationofindication,dosing/administration,sideeffects,\ndrug/foodinteractions,andappropriatesigns/symptomsofVTE."
    },
    {
        "page_number": 51,
        "text": "ANTICOAGULATIONMTAC(ACMTAC)PROTOCOL\n50Appendix11–WarfarinTherapyGuide\nWARFARINTHERAPYGUIDE13\nA.WARFARINDOSING\n1.Warfarindosingshouldbecalculatedusingweeklydosing.\n2.Dosecanbeincreaseordecreaseupto15%ofweeklydosing.\n3.AccordingtoICSIguideline14,increaseof15%weeklydose,would\ncorrespondtoincreaseinINRof1.0.Locally,forsimplicity,weuse1%\nincreaseinwarfarindosecorrespondtoincreaseinINRof0.1\n4.Thedosingofwarfarincanbedividedintotwophases:\na.Initiation(withfrequentINRtesting)and\nb.Maintenance(withlessfrequentINRtesting)\n5.Whentreatmentisinitiated,frequentINRmonitoringisconducteduntila\nstabledose-responserelationshipisachieved.Thereafter,thefrequency\nofINRtestingisreduced.\na.InitiationPhase\nAbaselineINRshouldbeobtainedpriortoinitiatingwarfarintherapy\nAllpatientsinitiatedonwarfarinmusthaveanINRmeasurementwithin\n7daysofinitiation\nTheinitiationdosemaystartwithdosesbetween3to5mgforthefirst\nthreedaysandsubsequentdosingbasedontheINRresponse.\nAdministeringaloadingdose(≥10mg)duringinitiationofwarfarinisnot\nrecommended.\nForpatientswhomaybesensitivetowarfarinsuchasinelderlypatients\norinpatientswhoaredebilitated,malnourished,haveCHF,haveliver\ndisease,havehadrecentmajorsurgery,oraretakingmedications\nknowntoincreasethesensitivitytowarfarin(eg,amiodarone),the\nstartingdoseshouldbelessthanorequalto3mg/day.\nAninitialeffectontheINRusuallyoccurswithinthefirst2–3days.A\ntherapeuticINRcanusuallybeachievedwithin5–10days.\nInitiationofwarfarincanbeguidedasTable1and2\nInsituationswherearapideffectisrequired,low-molecular-weight\nheparin(LMWH)shouldbeadministeredconcurrentlywithwarfarin.\nLMWHusuallycanbediscontinuedin5–6daysoraftertwoconsecutive\ntherapeuticINRvaluesareachieved."
    },
    {
        "page_number": 52,
        "text": "ANTICOAGULATIONMTAC(ACMTAC)PROTOCOL\n51Table1:Warfarininitiationfor1–14days(INRTarget2–3)\nTable2:FrequencyofINRmonitoring\nNotes:\n1.AlldosageadjustmentinTable1and2arerecommendationonly.\n2.ExclusionoffactorsaffectingINRmustbedonepriortodosage\nadjustment.\nAlwaysconsidertrendinINRswhenmakingwarfarinmanagementdecisions.\nConsiderrepeatingINRsamedayornextdayifobservedvaluemarkedly\ndifferentthanexpectedvalue(Potentialforlaberrorsexist)\nMaximumchangesofdailydoseis+1mg."
    },
    {
        "page_number": 53,
        "text": "ANTICOAGULATIONMTAC(ACMTAC)PROTOCOL\n52b.MaintenancePhase\nThisonlycanbeconsideredwhenINRachievedtargetranged.\nPatientswhohadstableINR(INRinrange>6months)canhadlonger\ndurationofINRmonitoring(upto12weeks).\nHoweverdoseadjustmentmustbedoneaccordinglywhenINRnotin\ntargetranged.\nDoseadjustmentandINRmonitoringcanbeguidedasTable1and2\nWeeklydosecanbeguideasinAppendix19\nB.LaboratoryMonitoring\nBaselinePT/INR/PTTT,fullbloodcount(FBC)withplateletsandliver\nfunctiontest(LFT)shallbeobtainedpriortowarfarininitiation.If\nbaselinelevelnotavailable,itshouldbeobtainedwithin24hours.\nInhospitalizedpatients,PTmonitoringisusuallyperformeddaily,\nstartingafterthesecondorthirddoseuntilthetargettherapeuticrange\nhasbeenachievedandmaintainedforatleast2consecutivedays;then\ntwoorthreetimesweeklyfor1to2weeks;thenlessoften,depending\nonthestabilityofINRresults.\nInoutpatientsstartingwarfarintherapy,initialmonitoringmaybe\nreducedtoeveryfewdaysuntilastabledoseresponsehasbeen\nachieved.WhentheINRresponseisstable,thefrequencyoftesting\ncanbereducedtointervalsaslongasevery4-8weeks."
    },
    {
        "page_number": 54,
        "text": "ANTICOAGULATIONMTAC(ACMTAC)PROTOCOL\n53Appendix12–WeeklyDosingChart\nWEEKLYDOSINGCHART"
    },
    {
        "page_number": 55,
        "text": "ANTICOAGULATIONMTAC(ACMTAC)PROTOCOL\n54"
    },
    {
        "page_number": 56,
        "text": "ANTICOAGULATIONMTAC(ACMTAC)PROTOCOL\n55"
    },
    {
        "page_number": 57,
        "text": "ANTICOAGULATIONMTAC(ACMTAC)PROTOCOL\n56"
    },
    {
        "page_number": 58,
        "text": "ANTICOAGULATIONMTAC(ACMTAC)PROTOCOL\n57"
    },
    {
        "page_number": 59,
        "text": "ANTICOAGULATIONMTAC(ACMTAC)PROTOCOL\n58"
    },
    {
        "page_number": 60,
        "text": "ANTICOAGULATIONMTAC(ACMTAC)PROTOCOL\n59"
    },
    {
        "page_number": 61,
        "text": "ANTICOAGULATIONMTAC(ACMTAC)PROTOCOL\n60"
    },
    {
        "page_number": 62,
        "text": "ANTICOAGULATIONMTAC(ACMTAC)PROTOCOL\n61Appendix13–WarfarinInteractions\nWARFARININTERACTIONS\nA.InteractionsofWarfarin\n1.Numerousmedications,foods,andhealthconditionscaneitherpotentiate\norinhibitwarfarineffects.\n2.Instructpatientstoreportanychangesindiet,medications,orhealth\nstatus.\n3.Belowisageneraldescriptionofsomeinteractionswithwarfarin.Please\nRefertoWarfarinInteractionshandbook12forfurtherlist.\nB.Diet\n1.Foodsthatinteractwithwarfarinaremostlytheonesthatarehighin\nvitaminK,especiallygreenleafyvegetables.\n2.Patientsshouldbeadvisedtotakesuchfoodsconsistentamounttoavoid\nlargefluctuationsinINR.\nC.Medication\n1.Numerousdrugsinteractwithwarfarin,eitherincreasingordecreasing\nanticoagulanteffect.\n2.ItisthereforerecommendedthattheINRshouldbecheckedwheneverany\nnewdrugorherbalmedicineisaddedorwithdrawnfromapatient’s\nregimen.\n3.Belowissomespecificguidance:\na.Antibiotics:Patientsstartedonantibioticsthatinteractwithwarfarin\n(i.e.,erythromycin,metronidazole,ciprofloxacin,sulfamethoxazole-\ntrimethoprim,fluconazole,ketoconazole,rifampin,dicloxacillin)should\nbeinstructedtoreturnin3daystoassesstheeffectontheirINR,\nunlesswarfarindoseadjustmentcanbemadeonthebasisofa\npatient’spriorINRresponsehistory.\nb.Amiodarone:Patientsstartedonamiodaroneshouldgenerallybe\ninstructedtoreturnin3daystoassesstheeffectontheirINR.The\nwarfarindoseshouldbereducedempiricallybyaboutone-thirdtoone-\nhalf.TheINRshouldbefollowedclosely,onceortwiceweekly,with\ndosageadjustmentsuntiltheINRisstable."
    },
    {
        "page_number": 63,
        "text": "ANTICOAGULATIONMTAC(ACMTAC)PROTOCOL\n62D.HealthCondition\n1.Table1showedthehealthconditionsthatcausewarfarinsensitivity\nTable1:HealthConditions\nDISEASE ↑INRDISEASE ↓INR\nCancer √Edema √\nHeartFailure √Nephroticsyndrome√\nLiverdysfunction √\nHyperthyroidism √\nFever √\nPoornutritionalstate √\nSevereorprolonged\ndiarrhea√\nRenalDisease-endstage√"
    },
    {
        "page_number": 64,
        "text": "ANTICOAGULATIONMTAC(ACMTAC)PROTOCOL\n63Appendix14–PrescribingInformationforDabigatran\nPRESCRIBINGINFORMATIONFORDABIGATRAN8\nA.Indicationanddose\nDirectthrombininhibitor\nIndicatedforthepreventionofstrokeandsystemicembolisminpatients\nwithatrialfibrillationandforthepreventionofVTEinpatientswhohave\nundergoneelectivetotalhipreplacementortotalkneereplacement\nsurgery.\nTreatmentofAF.Doseinatrialfibrillationis150mgtwicedaily.\nTreatmentofdeepveinthrombosis(DVT),andpreventionofrecurrent\nDVTandpulmonaryembolism(PE)followingandacuteDVTinadults.\nTherecommendeddailydoseis300mgtakenasone150mgcapsule\ntwicedaily.\nPreventionofvenousthromboemboliceventsinpatientswhohave\nundergonetotalkneereplacementortotalhipreplacementsurgery.\nInitiateorallywithin1–4hoursofcompletedsurgeryasasinglecapsule\n(110mg).Thereafter,\nHipreplacement:110mgtwicedailyfor28-35days\nKneereplacement:110mgtwicedailyfor10days\nB.DosingModificationandConsideration\nSpecialpatientpopulationswithareduceddailydose(220mgtakenas\none110mgcapsuletwicedaily):\nPatientsaged80yearsorabove\nConcomitantuseofverapamiloramiodaroneorquinidine\nForthefollowinggroups,thedailydoseof300mgor220mgshouldbe\nselectedbasedonanindividualassessmentofthethromboembolicrisk\nandtheriskofbleeding:\nPatientsbetween75-80years\nPatientswithmoderaterenalimpairment(CrCL30-50ml/min)\nPatientswithgastritis,esophagitisorgastroesophagealreflux\nOtherpatientsatincreasedriskofbleeding\nProphylaxisofDVTfollowinghiporkneereplacementsurgery:Special\npatientpopulationswithareduceddailydose:\nPatientsaged75yearsorolder"
    },
    {
        "page_number": 65,
        "text": "ANTICOAGULATIONMTAC(ACMTAC)PROTOCOL\n64Moderaterenalimpairment(creatinineclearance30–50mL/min)\nConcomitantuseofverapamiloramiodaroneorquinidine\nDoserecommendationforspecialpatientpopulations:\nInitiateorallywithin1–4hoursofcompletedsurgeryasasinglecapsule\n(75mg).Thereafter,\nHipreplacement:150mgoncedailyfor28-35days\nKneereplacement:150mgoncedailyfor10days\nC.Cautions/Specialwarning\nUseinrenalimpairment:\nClearanceofdabigatraninpatientswithrenalinsufficiencymaytake\nlonger.\nPleasemakesurepatientshavedonerenalfunctiontestpriorto\ninitiationoftreatmentwithDabigatran.\nCloseclinicalsurveillanceisrecommendedinpatientswithrenal\nimpairment.\nUseinhepaticimpairment:\nPatientswithelevatedliverenzymes>2ULNshouldnotbe\nprescribeddabigatran.\nD.Riskofbleeding:\nUsewithcautioninconditionswithanincreasedriskofbleeding.\nBleedingmayoccuratanysiteduringtherapywithDabigatran.\nAnunexplainedfallinhaemoglobinand/orhematocritorbloodpressure\nshouldleadtoasearchforableedingsite.Whenclinicallyrelevant\nbleedingoccurs,treatmentshouldbeinterrupted.\nE.Contraindication\nHypersensitivitytotheactivesubstanceortoanyoftheexcipients\nPatientswithsevererenalimpairment(CrCL<30ml/min)\nActiveclinicallysignificantbleeding\nOrganiclesionatriskofbleeding\nSpontaneousorpharmacologicalimpairmentofhaemostasis"
    },
    {
        "page_number": 66,
        "text": "ANTICOAGULATIONMTAC(ACMTAC)PROTOCOL\n65Hepaticimpairmentorliverexpectedtohaveanyimpactsurvival\nConcomitanttreatmentwithsystemicketoconazole,cyclosporine,\nitraconazole,tacrolimus\nF.Monitoring\nAswarfarinpatientsneedtomonitorforsignsofbleedingandanaemia\n(noclinicalmonitoringavailable–INRnotabletobeusedasdifferent\npathwayofaction)\nMonitoringofcreatinineclearanceshouldbedoneatleast\nOnceortwiceayearforpatientswhohadCrCl≥50ml/min\nEvery6monthsforpatientswhohadCrCl≤50ml/min\nG.Druginteractions\nGenerally,interactionsleadtoanincreasebleedingrisk–patientsshould\nbemonitoredcloselyforsignsofbleedingandanaemia.\nCautionwithconcomitantotheranticoagulants\nSystemicazoleantimycoticse.g.ketoconazole,ciclosporin,itraconazole,\ntacrolimusarecontraindicated\nCautionwithconcomitantstrongP-gpinhibitorse.g.amiodarone,\nquinidine,verapamil\nCautionconcomitantuseofamiodarone(amiodaronehasalonghalf-life\nandinteractionmayexistforweeksafterdiscontinuation,especiallyin\npatientswithmild-moderaterenalimpairment)\nCautionconcomitantuseofquinidineespeciallyinpatientswithmildto\nmoderaterenalimpairment\nCautionconcomitantuseofverapamil\nCautionconcomitantuseofclarithromycin,especiallyinpatientswith\nmild-moderaterenalimpairment.\nProteaseinhibitors(e.g.ritonavircontainingproducts)shouldnotbe\nprescribedconcomitantly(duetolackofavailablesafetydataforthis\ncombination)\nInteractionsbelowleadtoadecreaseinanticoagulantconcentration\nthereforetreatmentmaybesuboptimal\nCautionconcomitantuseofstrongCYP3A4inducerse.g.rifampicin,St.\nJohn’sWort,carbamazepine,phenytoin"
    },
    {
        "page_number": 67,
        "text": "ANTICOAGULATIONMTAC(ACMTAC)PROTOCOL\n66Appendix15–PrescribingInformationforRivaroxaban\nPRESCRIBINGINFORMATIONFORRIVAROXABAN9\nA.Indicationanddose\nInhibitsFactorXa\nPreventionofstrokeandsystemicembolisminadultpatientswithnon-\nvalvularatrialfibrillation(AF)withoneormoreriskfactor,suchas\ncongestiveheartfailure,hypertension,age≥75yrs,diabetesmellitus,\npriorstrokeortransientischaemicattack.\nTreatmentofdeepveinthrombosis(DVT),andpreventionofrecurrent\nDVTandpulmonaryembolism(PE)followingandacuteDVTinadults:\nDose:15mgtwicedailywithfood,forfirst21daysonday22,transition\nto20mgoncedailywithfood,forremainingtreatment.Dose:20mgOD\nwiththeeveningmeal.Therapyshouldbecontinuedlongterm.\nPreventionofvenousthromboembolisminpatientsundergoingelective\nhiporkneereplacementsurgery.\nHipreplacement:Dose:10mgoncedailyfor35days\nKneereplacement:Dose:10mgoncedailyfor12days(withor\nwithoutfood)\nB.DosingModificationandConsideration\nNon-valvularAtrialFibrillation:\nRenalimpairment:\nCrCl15to50mL/min:15mgoncedailywiththeeveningmeal\nCrCl<15mL/min:Avoiduse\nPeriodicallyassessrenalfunctionasclinicallyindicated(i.e.more\nfrequentlyinsituationsinwhichrenalfunctionmaydecline)andadjust\ntherapyaccordingly.\nTreatmentDVT,andpreventionofrecurrentDVTandPEfollowingan\nacuteDVTinadults\nRenalimpairment\nCrCl<30mL/min:Avoiduse"
    },
    {
        "page_number": 68,
        "text": "ANTICOAGULATIONMTAC(ACMTAC)PROTOCOL\n67ProphylaxisofDVTfollowinghiporkneereplacementsurgery:\nRenalimpairment\nCrCl<30mL/min:Avoiduse\nObservecloselyandpromptevaluateanysignsorsymptomofbloodloss\ninpatientswithCrCl30to50mL/min.\nDiscontinuerivaroxabaninpatientswhodevelopacuterenalfailurewhile\nonrivaroxaban.\nC.Cautions/Specialwarning\nIncreasedriskofthromboticeventsafterPrematureDiscontinuation:\nAnincreasedrateofstrokewasobservedduringthetransitionfrom\nRivaroxabantowarfarininclinicaltrialsinatrialfibrillationpatients.\nIfRvaroxabanisdiscontinuedforareasonotherthanpathological\nbleedingorcompletionofacourseoftherapy,considercoveragewith\nanotheranticoagulant\nD.Riskofbleeding:\nRivaroxabancancauseseriousandfatalbleeding.Promptlyevaluate\nsignsandsymptomsofbloodloss.\nE.Spinal/epiduralanesthesiaorPuncture:\nWhenneuraxialanesthesia(spinal/epiduralanesthesia)orspinal\npunctureisemployed,patientstreatedwithanticoagulantagentsfor\npreventionofthromboemboliccomplicationsareatriskofdevelopingan\nepiduralorspinalhematomawhichcanresultinlong-termorpermanent\nparalysis.\nAnepiduralcathetershouldnotberemovedearlierthan18hoursafter\nthelastadministrationofRivaroxaban.\nThenextRivaroxabandoseisnottobeadministeredearlierthan6hours\naftertheremovalofthecatheter.\nIftraumaticpunctureoccurs,theadministrationofRivaroxabanistobe\ndelayedfor24hours"
    },
    {
        "page_number": 69,
        "text": "ANTICOAGULATIONMTAC(ACMTAC)PROTOCOL\n68F.PregnancyandNursingmothers:\nUseRivaroxabanwithcautioninpregnantwomenduetothepotentialfor\nobstetrichaemorrhageand/oremergentdelivery.\nPromptlyevaluatesignsandsymptomsofbloodloss.\nDiscontinuedrugordiscontinuenursing\nG.Prostheticheartvalves:\nRivaroxabanusenotrecommended\nH.Contraindication\nHypersensitivitytotheactivesubstanceortoanyoftheexcipients.\nClinicallysignificantactivebleeding.\nHepaticdiseaseassociatedwithcoagulopathyandclinicallyrelevant\nbleedingriskincludingcirrhoticpatientswithChildPughBandC\nPatientswithsevererenalimpairment(referdosingconsideration)\nPregnancyandbreastfeeding\nLesionorconditionatsignificantriskofmajorbleeding\nConcomitanttreatmentwithanyotheranticoagulantagentexceptunder\nthecircumstancesofswitchingtherapytoorfromrivaroxabanorwhen\nUFHisgivenatdosesnecessarytomaintainapatentcentralvenousor\narterialcatheter.\nI.Monitoring\nAswarfarinpatientsneedtomonitorforsignsofbleedingandanaemia\n(noclinicalmonitoringavailable–INRnotabletobeusedasdifferent\npathwayofaction)\nMonitoringofcreatinineclearanceshouldbedoneatleast\nOnceortwiceayearforpatientswhohadCrCl≥50ml/min\nEvery6monthsforpatientswhohadCrCl≤50ml/min"
    },
    {
        "page_number": 70,
        "text": "ANTICOAGULATIONMTAC(ACMTAC)PROTOCOL\n69J.Druginteractions\nInteractionsbelowleadtoanincreasebleedingrisk–patientsshouldbe\nmonitoredcloselyforsignsofbleedingandanaemia.\nConcomitantuseofsystemicazoleantimycoticse.g.ketoconazole,\nitraconazole,voriconazole,posaconazole,\nHIVproteaseinhibitors\nConcomitantuseofdronedaroneshouldbeavoided\nCautionwithconcomitantanticoagulants,NSAIDsandplatelet\naggregationinhibitors(e.g.clopidogrel)\nInteractionsbelowleadtoadecreaseinanticoagulantconcentration\nthereforetreatmentmaybesuboptimal\nCautionconcomitantusestrongCYP3A4inducerse.g.phenytoin,\ncarbamazepine,phenobarbital,St.John’sWort"
    },
    {
        "page_number": 71,
        "text": "ANTICOAGULATIONMTAC(ACMTAC)PROTOCOL\n70Appendix16-PrescribingInformationforApixaban\nPRESCRIBINGINFORMATIONFORAPIXABAN10\nA.Indicationanddose\nInhibitsFactorXa\nPreventionofstrokeandsystemicembolisminpatientswithnon-\nvalvularatrialfibrillation(NVAF),withoneormoreriskfactors,suchas\npriorstrokeortransientischemicattack(TIA);age≥75years;\nhypertension;diabetesmellitus;symptomaticheartfailure(NYHAClass\n≥II).Restriction:Onlyforrenalpatients.\nDose:5mgBD.\nDosereduction:2.5mgtakenorallyBDinNVAFpatientswithat\nleasttwoofthefollowingcharacteristics:age≥80yearsold,body\nweight≤60kg,orserumcreatinine≥1.5mg/dL(133micromole/L).\nB.DosingModificationandConsideration\nNon-valvularAtrialFibrillation:\nRenalimpairment:\nCrCl<15-29mL/min:2.5mgtwicedaily\nPatientswithserumcreatinine≥1.5mg/dL(133micromole/L)\nassociatedwithage≥80yearsorbodyweight≤60kgshouldalso\nreceivethelowerdoseofapixaban2.5mgtwicedaily.\nInpatientswithcreatinineclearance<15mL/min,orinpatients\nundergoingdialysis,thereisnoclinicalexperiencetherefore,apixaban\nisnotrecommended.\nC.Cautions/Specialwarning\nAswithotheranticoagulants,patientstakingApixabanaretobe\ncarefullyobservedforsignofbleeding.\nItisrecommendedtobeusedincautioninconditionswithincreased\nriskofhaemorrhage.Apixabanadministrationshouldbediscontinuedif\nseverehaemorrhageoccurs.\nD.Spinal/epiduralanaesthesiaorpuncture:"
    },
    {
        "page_number": 72,
        "text": "ANTICOAGULATIONMTAC(ACMTAC)PROTOCOL\n71Whenneuraxialanaesthesia(spinal/epiduralanaesthesia)or\nspinal/epiduralpunctureisemployed,patientstreatedwith\nantithromboticagentsforpreventionofthromboemboliccomplications\nareatriskofdevelopinganepiduralorspinalhaematomawhichcan\nresultinlong-termorpermanentparalysis.\nTheriskoftheseeventsmaybeincreasedbythepost-operativeuseof\nindwellingepiduralcathetersortheconcomitantuseofmedicinal\nproductsaffectinghomeostasis.\nIndwellingepiduralorintrathecalcathetersmustberemovedatleast5\nhourspriortothefirstdoseofApixaban.\nTheriskmayalsobeincreasedbytraumaticofrepeatedepiduralor\nspinalpuncture.\nPatientsaretobefrequentlymonitoredforsignsandsymptomsof\nneurologicalimpairment(e.g.,numbnessorweaknessofthelegs,\nbowelorbladderdysfunction).\nPriortoneuraxialintervention,thephysicianshouldconsiderthe\npotentialbenefitversusriskinanticoagulatedpatientsorinpatientsto\nbeanticoagulatedforthromboprophylaxis.\nThereisnoclinicalexperiencewiththeuseofapixabanwithindwelling\nintrathecalorepiduralcatheters.\nIncasethereissuchneedandbasedonthegeneralPKcharacteristics\nofapixaban,atimeintervalof20to30hours(i.e.,2xhalf-life)between\nthelastdoseofapixabanandcatheterwithdrawalshouldelapse,andat\nleastonedoseshouldbeomittedbeforecatheterwithdrawal.\nThenextdoseofapixabanmaybegivenatleast5hoursaftercatheter\nremoval.\nE.Prostheticheartvalves:\nUseofApixabanisnotrecommended.\nF.Hepaticimpairment:\nNotrecommendedinpatientswithseverehepaticimpairment(see\nContraindications).\nTobeusedwithcautioninpatientswithmildtomoderatehepatic\nimpairment(ChildPughAorB)."
    },
    {
        "page_number": 73,
        "text": "ANTICOAGULATIONMTAC(ACMTAC)PROTOCOL\n72G.Hipfracturesurgery:\nUseofApixabanisnotrecommended.\nH.Contraindication\nHypersensitivitytotheactivesubstanceortoanyoftheexcipients.\nActiveclinicallysignificantactivebleeding\nHepaticdiseaseassociatedwithcoagulopathyandclinicallyrelevant\nbleedingrisk.\nLesionorconditionatsignificantriskofmajorbleeding,suchascurrent\norrecentgastrointestinalulceration,presenceofmalignantneoplasms\nathighriskofbleeding,recentbrainorspinalinjury,recentbrain,spinal\norophthalmicsurgery,recentintracranialhaemorrhage,knownor\nsuspectedoesophaegealvarices,arteriovenousmalformations,\nvascularaneurysmsormajorintraspinalorintracerebralvascular\nabnormalities.\nConcomitanttreatmentwithanyotheranticoagulantagent,except\nunderspecificcircumstancesofswitchinganticoagulanttherapyor\nwhenUFHisgivenatdosesnecessarytomaintainapatentcentral\nvenousorarterialcatheter.\nI.Monitoring\nAswarfarinpatientsneedtomonitorforsignsofbleedingandanaemia\n(noclinicalmonitoringavailable–INRnotabletobeusedasdifferent\npathwayofaction)\nMonitoringofcreatinineclearanceshouldbedoneatleast\nOnceortwiceayearforpatientswhohadCrCl≥50ml/min\nEvery6monthsforpatientswhohadCrCl≤50ml/min\nJ.Druginteractions\nInteractionsbelowleadtoanincreasebleedingrisk–patientsshould\nbemonitoredcloselyforsignsofbleedingandanaemia.\nConcomitantuseofsystemicazoleantimycoticse.g.ketoconazole,\nitraconazole,voriconazole,posaconazole,\nHIVproteaseinhibitors"
    },
    {
        "page_number": 74,
        "text": "ANTICOAGULATIONMTAC(ACMTAC)PROTOCOL\n73Cautionwithconcomitantanticoagulants\nCautionwithconcomitantNSAIDsandplateletaggregationinhibitors\n(e.g.clopidogrel)\nInteractionsbelowleadtoadecreaseinanticoagulantconcentration\nthereforetreatmentmaybesuboptimal\nCautionconcomitantusestrongCYP3A4inducerse.g.phenytoin,\ncarbamazepine,phenobarbital,St.John’sWort"
    },
    {
        "page_number": 75,
        "text": "ANTICOAGULATIONMTAC(ACMTAC)PROTOCOL\n74Appendix17-TripleTherapyGuide\nTRIPLETHERAPYGUIDE15,16\nA.DurationofTripleTherapy\nThecornerstoneofchronicantithromboticprophylaxisinpatients\nundergoingpercutaneouscoronaryintervention(PCI),presentingwith\norwithoutanacutecoronarysyndrome(ACS),isdualantiplatelet\ntherapy(DAPT)withlow-doseaspirinandaP2Y12inhibitor.\nCoronaryarterydisease(CAD)coexistin20%–30%ofpatientswithAF,\nandapproximately5%–7%ofPCIpatientspresentwithAForother\nindicationsforchronicanticoagulationtherapy..\nWhenindicationsforDAPTandanticoagulationtherapycoexist,the\nsuggestionforoptimalmanagementoftripletherapyasinTable1,2\nandTable3.\nTable1:AntithromboticTherapyAfterACS16"
    },
    {
        "page_number": 76,
        "text": "ANTICOAGULATIONMTAC(ACMTAC)PROTOCOL\n75Table2:AntithromboticTherapyAfterPCI16\nTable3:GuidetoshortenTripleTherapyAfterACSorPCI17"
    },
    {
        "page_number": 77,
        "text": "ANTICOAGULATIONMTAC(ACMTAC)PROTOCOL\n76B.Strategiestoavoidbleedingcomplicationsinpatientstreatedwith\nTripleTherapy\nAssessischemicandbleedingrisksusingvalidatedriskpredictors(eg.\nCHA2DS2VASc,HAS-BLED)withfocusonmodifiableriskfactors.\nKeeptripletherapydurationasshortaspossible;dualtherapyafter\nPCI(anticoagulationandclopidogrel)tobeconsideredinsteadoftriple\ntherapy\nConsideratargetINRinthelowerpartoftherecommendedtarget\nrangeandmaximisetimeintherapeuticrange(TTR)(>65-70%)when\nwarfarinisused\nClopidogrelastheP2Y12inhibitorofchoice\nConsiderthelowerDOACregimentestedinapprovalstudiesandapply\notherDOACregimenbasedondrug-specificcriteriafordrug\naccumulation\nRivaroxaban15mgodinsteadof20mgod18\nDabigatran110mgtwicedailyinsteadof150mgtwicedaily16\nUselowdose(<100mgdaily)aspirin\nRoutineuseofPPIs"
    },
    {
        "page_number": 78,
        "text": "ANTICOAGULATIONMTAC(ACMTAC)PROTOCOL\n77Appendix18-ConversionofAnticoagulantsGuide\nCONVERSIONOFANTICOAGULANTSGUIDE"
    },
    {
        "page_number": 79,
        "text": "ANTICOAGULATIONMTAC(ACMTAC)PROTOCOL\n78Appendix19-AnticoagulationReversalGuide\nGUIDEFORTREATMENTOFBLEEDINGINANTICOAGULATION\nPATIENTS\n1.Intheanticoagulatedpatientwhopresentswithclinicallyrelevant\nbleedingorneedsanurgentunplannedprocedure,measurementof\nanticoagulantactivityisakeystepintheevaluation.\n2.Aprothrombintime(PT)and/oranactivatedpartialthromboplastintime\n(aPTT)shouldberequestedinallsuchpatients.\n3.InterpretationofthePTandaPTTaswellasthepotentialneedto\nrequestspecializedcoagulationtestswilldependontheclinicalsituation,\ntheanticoagulant,andtestavailability.\n4.Unlessaconcomitantdefectincoagulation(e.g.,disseminated\nintravascularcoagulation)issuspected,patientstakingwarfarinmaybe\nevaluatedwiththePT/InternationalNormalizedRatio(INR).\n5.TheINRmaybeusedtoguideperioperativeorbleedingmanagement."
    },
    {
        "page_number": 80,
        "text": "ANTICOAGULATIONMTAC(ACMTAC)PROTOCOL\n79A.REVERSALOFWARFARIN19,20\nTable1-Managementofwarfarinassociatedbleedingorsupra-therapeutic\nINR21"
    },
    {
        "page_number": 81,
        "text": "ANTICOAGULATIONMTAC(ACMTAC)PROTOCOL\n80B.REVERSALOFDOACS19,22,23\n1.LaboratorymeasurementoftheanticoagulantactivityoftheDOACsismore\ncomplex.Thebestassaysarespecializedandarenotwidelyavailable.\nMoreaccessibletestssuchasthePTandaPTThaveimportantlimitations.\n2.Specificmeasuresaredirectlytargetingtheanticoagulantagent,bymeans\nof(Fabfragmentsof)monoclonalantibodies(dabigatran)oractivated\nFactorX(FXa)moleculesthatcompetitivelybindtothe\nrivaroxaban/apixabanarenotavailableinMalaysia.\n3.Nonspecifictestsuchastheactivatedpartialthromboplastintime(aPTT),\ndilutedthrombintime(dTT),ecarinclottingtime(ECT),prothrombintime\n(PT)canbeusedtomonitortheeffectofanticoagulationeffectasin\nTables2.\n4.Thesuggestionsofclinicalrelevantforlaboratorymeasurementofthe\nDOACsbasedonspecializedassayavailabilityissummarizedinTable3.\n5.TimeoflastDOACsdoseshouldalwaysbeconsideredwheninterpreting\ntestresults.Table4showedhowtointerpretthetestresults.\n6.Dependentontheseverityoftheclinicalsituationandinviewofthe\nrelativelyshorthalf-lifeofthedirectfactorXainhibitors(5–15h),cessation\nofDOACsmayoftenbesufficienttoreversetheanticoagulanteffectincase\nofbleeding.\n7.TheINRisnotasuitabletesttoquantitatethe(residual)anticoagulanteffect\nbyDOACs.\n8.Insevereorlife-threateninghemorrhage,oremergencyprocedureson\ntherapy,reversalofdabigatrananticoagulanteffectwith5gramsof\nidarucizumabasafixed-dose(intravenousinfusionoftwo2.5-gram)is\nrecommended.\n9.Ifidarucizumabisunavailable,theneitherPCCoractivatedprothrombin\ncomplexconcentrate(aPCC)at50U/kg(maxdose4,000U)maybeused\n10.Sincedabigatranismostlynotboundtoproteinsintheserum(>85%),\nhemodialysishasbeensuggestedifthedruglevelisveryhigh,especiallyin\npatientswithimpairedrenalfunction.Activatedcharcoal(50g)mayalsobe\nusedifthedrugwasingestedwithinlast2to4hours\n11.Therearecurrentlynospecificantidotesclinicallyavailableforreversalof\nRivaroxaban/apixabananticoagulanteffect.Coagulationfactor\nsupplementationwithPCCoraPCChasbeensuggestedasapotential\nnonspecificreversalstrategyforthedirectFXainhibitors.\n12.Table4presentedtherecommendedreversalagentforDOACs."
    },
    {
        "page_number": 82,
        "text": "ANTICOAGULATIONMTAC(ACMTAC)PROTOCOL\n8113.Practicalguideforhowtomanagebleedingcomplicationsinpatientson\nDOACsisshowedinTable5.\nTable2–Therecommendedtesttomonitortheanticoagulanteffectin\npatientsreceivingDOACs\nSuggestionTestsDabigatran Rivaroxaban Apixaban\naPTT\nTT\ndTT,ECT\nAnti-FXa\nPT\nINR\nNote:ActivatedPartialThromboplastinTime(aPTT),DilutedThrombinTime(dTT),\nEcarinClottingTime(ECT),ProthrombinTime(PT),Factor-Xa(FXa),\nTable3:SuggestionsforLaboratoryAssaysfor“EmergencySituation’’23\nTest ApixabanDabigatranRivaroxaban\nProthrombinTime(PT)\n -/+\nActivatedPartial\nThrompoplastinTime(aPTT)-/+\n -/+\nThrombinTime(TT)\n -/+\nAntiFactorXa\n x\nFibrinogen - Falselylow -\nD-dimer Low Low Low\nAnormalPToraPTTdoesnotexcludethepossibilityofresidualanticoagulant\neffect\nNeworalanticoagulantsdonotcausethrombocytopeniaandtheD-dimerlevel\nislikelytobelow\nTTnotavailablelocally\n-/+Notidealbutwidelyavailable\n\nRequirescalibrationwithrequireddrug.\n\nNotlocallyavailable"
    },
    {
        "page_number": 83,
        "text": "ANTICOAGULATIONMTAC(ACMTAC)PROTOCOL\n82Table4-AvailableReversalAgentsandSuggestedUse\nReversalAgentFactorIIaInhibitor\n(Dabigatran)FactorXaInhibitor(Apixaban,\nandRivaroxaban)\nPCC(3F/4F)Secondline Firstline\naPCC Secondline Secondline\nIdarucizumabFirstline Notindicated\nPlasma Notindicated Notindicated\nPCC=prothrombincomplexconcentrate;\naPCC=activatedprothrombincomplexconcentrate.\nTable5-ManagementofbleedinginpatientsreceivingDOACs\nDabigatran Rivaroxaban/apixaban\nNonelife-threateningbleeding\nChecklastintake;\nrestorationofnormalcoagulationtobeexpectedat12–24h(incaseof\ncreatinineclearance > 80ml/min)or24–36h(incaseofcreatinine\nclearance50–80ml/min)\n   Localhemostaticinterventions,fluidmanagement,transfusion\n   ConsiderActivatedCharcoal\nLife-threateningbleeding\nAlloftheabove Alloftheabove\nIdarucizumab\n-5gramsasafixeddose\n(intravenousinfusionoftwo\n2.5gram)Prothrombincomplexconcentrate\n-Dose50U/kg(maxdose4,000\nU)\nProthrombincomplexconcentrate\n-Dose50U/kg(maxdose\n4,000U)"
    },
    {
        "page_number": 84,
        "text": "ANTICOAGULATIONMTAC(ACMTAC)PROTOCOL\n83Appendix20–RecommendedDispensingLabel\nRECOMMENDEDDISPENSINGLABEL\nWARFARIN1MG/2MG/3MG/5MG\nNAMA:__________________________\nTARIKH:__________________________\nKUANTITI:__________________________\nMAKAN______BIJIPADA__________________\nJABATANFARMASI,HOSPITAL………………………….........................….WARFARIN1MG/2MG/3MG/5MG\nNAMA:__________________________\nTARIKH:__________________________\nKUANTITI:__________________________\nMAKAN____BIJIPADAHARIISNIN\n____BIJIPADAHARISELASA\n____BIJIPADAHARIRABU\n____BIJIPADAHARIKHAMIS\n____BIJIPADAHARIJUMAAT\n____BIJIPADAHARISABTU\n____BIJIPADAHARIAHAD\nSEKALISEHARI\nJABATANFARMASI,HOSPITAL………………………….........................….WARFARIN1MG/2MG/3MG/5MG\nLOADINGDOSE\nNAMA:__________________________\nTARIKH:__________________________\nKUANTITI:__________________________\nMAKAN______BIJIPADA__________________\nJABATANFARMASI,HOSPITAL………………………….........................…."
    },
    {
        "page_number": 85,
        "text": "ANTICOAGULATIONMTAC(ACMTAC)PROTOCOL\n84REFERENCES\n1.KatsnelsonM,SaccoRL,MoscucciM.Progressforstrokepreventionwith\natrialfibrillation:emergenceofalternativeoralanticoagulants.Circulation.\n2012;125(12):1577-1583.doi:10.1161/CIR.0b013e31825498e8.\n2.RoseAJ,BerlowitzDR,FrayneSM,HylekEM.Measuringqualityoforal\nanticoagulationcare:extendingqualitymeasurementtoanewfield.JtComm\nJQualPatientSaf.2009;35(3):146-155.doi:10.1016/S1553-7250(09)35019-9.\n3.AiditS,ShaharuddinS,NeohCF,MingLC.Evolvementofawarfarin\nmedicationtherapyadherenceclinicinMalaysiaanditsimpacton\ninternationalnormalisedratiocontrolovertime.JPharmPractRes.\n2015;45(4):431-432.doi:10.1002/jppr.1118.\n4.ErkensPMG,tenCateH,BüllerHR,PrinsMH.BenchmarkforTimein\nTherapeuticRangeinVenousThromboembolism:ASystematicReviewand\nMeta-Analysis.PLoSOne.2012;7(9).doi:10.1371/journal.pone.0042269.\n5.PrasadV,KaplanRM,PassmanRS.NewFrontiersforStrokePreventionin\nAtrialFibrillation.CerebrovascDis.2012;33:199-208.doi:10.1159/000334979.\n6.ManiH,Lindhoff-LastE.Neworalanticoagulantsinpatientswithnonvalvular\natrialfibrillation:areviewofpharmacokinetics,safety,efficacy,qualityoflife,\nandcosteffectiveness.DrugDesDevelTher.2014;8:789-798.\ndoi:10.2147/DDDT.S45644.\n7.SkaistisJ,TagamiT.Riskoffatalbleedinginepisodesofmajorbleedingwith\nneworalanticoagulantsandVitaminKantagonists:Asystematicreviewand\nmeta-Analysis. PLoS One. 2015;10(9):1-16.\ndoi:10.1371/journal.pone.0137444.\n8.BoehringerIngelheimCanadaLtd.DabigatranEtexilateCapsules.\n2019;(214068):1-70.\n9.BayerInc.rivaroxabantablets.2018:1-97.\n10.PfizerBSC.apixabantablets.2018:1-78.\n11.FiumaraK,GoldhaberSZ.Patient’sGuidetoTakingCoumadin/Warfarin.\nAmHeartJ.2009;3:220-222.doi:10.1161/CIRCULATIONAHA.108.803957.\n12.ClinicalPharmacyWorkingCommittee(CardiologySubspecialty),\nPharmaceuticalServicesDivisionMofH.WarfarinInteractionHandbook.\n13.GarciaD,ReganS,CrowtherM,HughesRA,HylekEM.Warfarin\nMaintenanceDosingPatternsinClinicalPractice*ImplicationsforSafer\nAnticoagulationintheElderly.Chest.2005;127(6):2049-2056.\ndoi:10.1378/chest.127.6.2049.\n14.ImprovementIforCS.AntithromboticTherapySupplementHealthCare\nGuideline.;2013.\n15.CapodannoD.TripleantithrombotictherapyafterACSandPCIinpatientson\nchronicoralanticoagulation :update.2018:1-8.doi:10.1136/bosis."
    },
    {
        "page_number": 86,
        "text": "ANTICOAGULATIONMTAC(ACMTAC)PROTOCOL\n8516.GermanyRAB,FranceJC,GermanyAK,etal.2017ESCfocusedupdateon\ndualantiplatelettherapyincoronaryarterydiseasedevelopedincollaboration\nwithEACTS.2017;0:1-45.doi:10.1093/ejcts/ezx334.\n17.HeidbuchelH,VerhammeP,AlingsM,etal.UpdatedEuropeanHeart\nRhythmAssociationPracticalGuideontheuseofnon-vitaminKantagonist\nanticoagulantsinpatientswithnon-valvularatrialfibrillation.2015;(i).\ndoi:10.1093/europace/euv309.\n18.BrunettiND,TarantinoN,GennaroLDe,CorrealeM,SantoroF,BiaseMDi.\nDirectoralanticoagulantsversusstandardtripletherapyinatrialfibrillation\nandPCI :meta-analysis.2018:1-7.doi:10.1136/openhrt-2018-000785.\n19.DohertyJU,EikelboomJW,PollackCV,HernandezAF.2017ACCExpert\nConsensusDecisionPathwayonManagementofBleedinginPatientsonOral\nAnticoagulants.2017;70(24):3042-3067.doi:10.1016/j.jacc.2017.09.1085.\n20.HolbrookA,SchulmanS,WittDM,etal.Evidence-BasedManagementof\nAnticoagulantTherapy.CHESTJ.2012;141(2_suppl):e152S-e84S.\ndoi:10.1378/chest.11-2295.\n21.GuyattGH,AklEa,CrowtherM,GuttermanDD,SchuünemannHJ.\nExecutivesummary:AntithromboticTherapyandPreventionofThrombosis,\n9thed:AmericanCollegeofChestPhysiciansEvidence-BasedClinical\nPracticeGuidelines. Chest.2012;141(2Suppl):7S-47S.\ndoi:10.1378/chest.1412S3.\n22.EerenbergES,KamphuisenPW,SijpkensMK,MeijersJC,BullerHR,LeviM.\nReversalofRivaroxabanandDabigatranbyProthrombinComplex\nConcentrateARandomized,Placebo-Controlled,CrossoverStudyin\nHealthy Subjects. 2011:1573-1579.\ndoi:10.1161/CIRCULATIONAHA.111.029017.\n23.GuidelineC,NumberR,DateI,etal.ProtocolForAppropriatePrescribingOf\nDirectActingOralAnticoagulants(Doacs)AndManagementOf\nHaemorrhageAnd.NICEGuidel.2019:1-18."
    }
]